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Preface 
 
Nowadays, the application of new manufacturing techniques, generally derived from other 
industrial fields, is one of the most promising innovation tools in the pharmaceutical 
technology area. This may indeed lead to a reduction of costs development and 
manufacturing, simplification of industrial scalability and, not least, to the patentability of 
drug products. In this respect, injection molding (IM) and micromolding (µIM), commonly 
employed within the plastic industry for a fast production of objects with different size, 
shape and, potentially, many details, were identified as especially interesting techniques to 
be exploited in the pharmaceutical field. In particular, µIM applies to the manufacturing of 
parts of few milligrams weight or with features where dimensions or dimension tolerances 
should be in the micrometer range, i.e. the potential scope of drug products. The topic 
appeared from the beginning as particularly innovative and challenging, and thus the 
availability of an in-depth scientific background was judged essential. IM technology and its 
use within the plastic industry (e.g. process, equipment and formulation aspects) as well as 
the applications already proposed in the pharmaceutical field were initially investigated 
(Part I). Afterwards, based on the knowledge acquired and on some experience already 
gained by the research group within which I carried out my PhD project, a few original 
products prepared by IM/µIM were developed, either drug delivery systems (DDSs) or 
conventional dosage forms (Part II and III).  
The µIM technique had already been applied to the manufacturing of a functional 
container in the form of a capsule shell, i.e. consisting of two parts to be assembled, based 
on hydrophilic polymers (different grades of hydroxypropyl cellulose) [1-4]. The obtained 
capsular system (Chronocap™) demonstrated the ability of delaying the release of the 
conveyed drug and was recently protected by a patent. Since the polymeric shell works like 
a barrier, functional containers, filled with various active principles/formulations (e.g. solid, 
semisolid and liquid), may represent an alternative configuration to reservoir systems and a 
step forward in controlled release. In fact, the nature of the container enables an 
independent development of the inner formulation, while the performance of the device is 
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determined by the composition and design features (i.e. morphology and thickness) of the 
shell. This would offer major benefits in terms of time and costs required for the 
development and avoid the need for setting up specific coating processes for different drug 
products. Based on the encouraging results obtained with the Chronocap™, the possibility 
of exploiting other polymers, characterized by a different behavior in aqueous fluids (e.g. 
insoluble but permeable or with a pH-dependent solubility), for the manufacturing of new 
capsular delivery systems was investigated. In particular, since a large number of enteric 
coated systems are present in the pharmaceutical market, the production of an enteric 
soluble device turned out to be of special interest. Being filled and sealed after 
manufacturing, it would represent a ready-to-use alternative to traditional gastro-resistant 
coated dosage forms, also for extemporaneous applications. The obtained shells, based on 
hydroxypropyl methylcellulose acetate succinate, showed promising in vitro and in vivo 
results (Part II and relevant Appendix). 
Improving the efficiency of manufacturing methods and exploiting more cost-effective as 
well as eco-friendly processes are among the main current objectives of the pharmaceutical 
industry. Besides the use of IM/µIM for the production of DDSs that would not be 
feasible by means of already available techniques, the interest in the application of these 
techniques can also be justified by a possible cost reduction, an easier scale-up and the 
patentability of the resulting products. Indeed, this trend is confirmed by the growing 
interest towards the introduction in the pharmaceutical field of continuous manufacturing 
(CM) [5]. Hot melt extrusion (HME) and IM/µIM techniques already demonstrated to 
fulfill the needs of this manufacturing approach. However, in order to employ such 
techniques for the production of dosage forms within a CM plant, knowledge in this 
respect needs to be broaden. A final part of my PhD work was therefore dedicated to 
investigate the feasibility of well-known DDSs, such as prolonged-release hydrophilic 
matrices, and conventional dosage forms, i.e. immediate release (IR) tablets, by HME and 
IM (Part III, Chapter I and II). 
All the results reported in the thesis have been already disclosed, i.e. published, submitted 
for publication or presented in the form of oral and poster communications to 
national/international meetings. 
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INJECTION MOLDING AND ITS APPLICATION TO DRUG DELIVERY 
 
Abstract 
Injection molding (IM) consists in the injection, under high pressure conditions, of heat-
induced softened materials into a mold cavity where they are shaped. The advantages the 
technique may offer in the development of drug products concern both production costs 
(no need for water or other solvents, continuous manufacturing, scalability, patentability) 
and technological/biopharmaceutical characteristics of the molded items (versatility of the 
design and composition, possibility of obtaining solid molecular dispersions/solutions of 
the active ingredient). In this article, process steps and formulation aspects relevant to IM 
are discussed, with emphasis on the issues and advantages connected with the transfer of 
this technique from the plastics industry to the production of conventional and controlled-
release dosage forms. Moreover, its pharmaceutical applications thus far proposed in the 
primary literature, intended as either alternative manufacturing strategies for existing 
products or innovative systems with improved design and performance characteristics, are 
critically reviewed. 
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1. Introduction 
Injection molding (IM) is a rapid and versatile manufacturing technique used in the plastics 
industry to produce objects with different size, shape and, if needed, many details [1,2]. It 
consists in the injection, under high pressure and temperature conditions, of melted 
thermoplastic or thermoset materials into a closed mold. The finished product cools down 
and/or solidifies inside the mold and is ejected at the end of the manufacturing cycle. 
A thermoplastic polymer is one that, when heated, undergoes a physical change, a 
transition to a viscous state, thanks to which it can be molded to give the desired shape. 
This process can be repeated many times when reworking is needed (e.g. polyethylene, PE; 
polyvinyl chloride, PVC). On the other hand, a thermoset polymer solidifies following 
heat-induced cross-linking. This chemical modification is thus responsible for the hardness 
of the resulting product. The latter cannot be molded again because reheating would cause 
degradation (e.g. phenol formaldehyde resins like bakelite) [3,4]. 
IM is a relatively young technique, born between the end of 1800 and the beginning of 
1900, with a real explosion around 1940 associated with an increased demand for 
inexpensive products. The improvement brought about by IM in plastics processing as 
compared with previous manufacturing techniques relies on the concurrent use of pressure 
and heat in order to turn a polymer, or a polymeric formulation, into a solid object with 
defined characteristics in terms of shape, dimension and features. 
IM has commonly been used for cosmetic/pharmaceutical packaging and, more recently, 
also for the production of biomedical devices such as scaffolds and microneedles [5-10]. 
Within the development of portable micropump delivery systems for chemotherapeutic 
drugs, insulin or immunization agents, promising results were also obtained in the 
manufacturing of microfluidic devices [11]. The idea of IM application to the preparation 
of drug dosage forms was first suggested by Speiser [12]. 
The chief determinants of the success of this technique in the pharmaceutical area are 
related to its scalability and patentability [13-15]. Indeed, IM is a potentially automated 
cyclic process (continuous production) that can easily be transferred to the industrial scale 
by the use of larger equipment and molds. A single IM cycle can last few seconds, and in 
many cases molds even enable the concurrent production of more than one unit, thus 
aiding the reduction of process time. 
The versatility of IM technique can be exploited for the production of drug delivery 
systems with defined shape and/or dimension characteristics [16-18]. Moreover, the 
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process does not require the use of solvents, which is advantageous in terms of 
manufacturing times and costs as well as of preserved stability [19]. 
Furthermore, the process conditions typically involved, pressure and heat, both reduce 
microbial contamination (autosterilization) and promote drug-polymer interactions with 
the possible formation of solid solutions or dispersions [20,21]. As in hot melt extrusion 
(HME) technique, this would increase the dissolution rate and, possibly, improve the 
bioavailability of poorly soluble drugs [22,23]. 
The great potential of IM for producing drug delivery systems is demonstrated by the 
multiplicity of patents filed over the last ten years, although the number of products at an 
advanced development stage or already on the market is still limited (e.g. Capill®, 
Chronocap™, Egalet®, Septacin™); hence, there is still room for improvement and in-
depth investigation. 
On the basis of these premises, the aim of the present review is to critically describe the use 
of IM as an alternative technique to produce dosage forms, while highlighting those 
applications that might reach innovative formulation targets and/or advantageous 
therapeutic goals. 
 
2. Process and equipment 
IM process is performed in appropriate equipment, IM machines, that generally consist of 
two parts: the plasticating/injecting unit (PIU) and the clamping unit (CU). Depending on 
the configuration of such units, horizontal, vertical or hybrid IM machines are 
distinguished. The latter present horizontal PIU and vertical CU or vice versa [2]. 
PIU is composed of a hopper that feeds a heated barrel, where heating, mixing, 
compression and melting steps take place. Thanks to various heater bands located along 
the barrel, it is possible to set and maintain different temperatures. 
A pressure-generating element is present in the barrel. While this was a plunger in the past 
(Hyatt's IM machine, 1872), modern equipment are screw-type [1]. 
By moving forward, the screw acts like a plunger exerting the injection pressure needed, 
whereas its rotation results in the movement/compression of the solid material/melt and 
concurrent development of shear forces that help increase the temperature of the latter 
(mechanical heating). Although the screw design should adapt to the characteristics of the 
processing material, the metering screw is the most popular one. In such screw, the rear 
section (feed zone) has a smaller diameter than the front end (meter zone), where the 
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material is forced to flow into a progressively narrower space: this is associated with an 
increased speed that generates frictional heat (squeezing action). The intermediate area of 
the screw (melt zone) is a transition area between the meter and feed zones. 
The screw ends in a tip that fits the nozzle cap. A backward flow of the melt is prevented 
by a non-return valve, located before the tip. The nozzle area, heated by its own heater 
band, is even smaller. Therefore, unwanted temperature increases might occur, possibly 
resulting in degradation phenomena, depending on the thermal stability and viscosity 
characteristics of the material. 
The terminal element of the IM machine is the mold. It is generally composed of two 
halves that combine to form a cavity of defined 3D shape that forms the outer surfaces of 
the molded object (single unit production cycle). It is also possible to design molds with 
several cavities in order to produce, within the same cycle, more than one unit. One part of 
the mold is mounted on a stationary platen, while the other is mobile, thus allowing the 
two halves to be matched (closed mold) or uncoupled (open mold). The clamping unit 
keeps the mold closed during injection. A clamping force exceeding the injection pressure 
is needed in order to prevent the mold from opening while the substrate is being injected 
and to retain the cavity pressure. The resulting gap would indeed hinder the 
accomplishment of the molded objects and/or cause the melt to squeeze out from the 
mold cavity (short shot and/or flash). 
The mold temperature is controlled by a cooling system that normally utilizes water as the 
circulating fluid. After injection, the melt cools down and/or solidifies in the mold and, 
when sufficiently hardened, it can be ejected by pins located in the mobile half of the mold. 
In order to acquire its final mechanical characteristics, however, the molded object may 
require a curing treatment. The object can undergo changes in size with respect to the 
cavity image [24]. This is known as shrinkage and can occur inside the mold or after 
ejection (mold and post-mold shrinkage, respectively). On the other hand, warpage is a 
deformation that consists in the bending or twisting of the unit thus resulting in alterations 
of bi- and tridimensional shape; it can be considered as a non-uniform shrinkage. 
IM machines are either single-stage, in which plastication and injection are carried out in 
the same cylinder by means of a reciprocating screw, or two-stage, wherein a plasticating 
screw feeds the melt into a holding/accumulator chamber [3]. The second stage (ram 
injection stage) involves the injection of the melt into the mold cavity. In Figure 1 a 
reciprocating screw machine is illustrated. 
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Figure 1: reciprocating screw machine (horizontal type). 
 
Figure 2 shows an outline of an IM cycle in a reciprocating screw machine. The 
filling/opening/closing cycle of the mold synchronizes with the movement of the screw 
(that moves forward to the injection position and is pushed back to the pre-injection one). 
When the molded object is automatically ejected, the IM cycle starts again thus providing a 
continuous manufacturing process. 
 
 
Figure 2: IM cycle in a reciprocating screw machine. 
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In order to produce microparts or micro-structured parts, i.e. parts of few milligrams 
weight or with features where dimensions or dimension tolerances are in the micrometer 
range, respectively, special microinjection molding (μIM) machines were developed in the 
‘90s [25,26]. The desired features of such machines encompass accurate metering and 
dosing, small shot size, high injection rate, short response time, small yet accurate clamping 
force, good stability and repeatability [27]. The main difficulties in the achievement of 
microparts were encountered for > 1 aspect ratios (i.e. ratio of total flow length to average 
wall thickness). μIM is not only a simple scale-down of classical IM. Indeed, the scale 
reduction of IM machine components (e.g. barrel length, screw/plunger and nozzle 
diameter, entire clamp unit, control equipment) alone was demonstrated not to be 
sufficient to ensure the accuracy of the metering size, limit the waste/degradation of 
polymer and prevent damage to molded parts during ejection. Moreover, the introduction 
of separate plasticating and injecting units along with a fine set-up of the process 
conditions were found necessary. 
Some pharmaceutical applications of IM are based on the use of non-conventional 
equipment adapted from other techniques. Extruders, for example, can be employed for 
the plasticating phase. However, the material has then to be maintained under suitable 
temperature conditions and transferred into a different equipment for the injection phase. 
This two-step process might impair an advantageous IM feature, i.e. the possibility of 
automation. 
 
3. Formulation aspects 
Polymers, commonly thermoplastic (at least 90%), are the basic components of items 
produced by IM. Currently, the plastics industry supplies a wide variety of polymeric 
materials. Both amorphous (e.g. polyurethane, PU; PVC) and semi-crystalline (e.g. nylon; 
PE) polymers may be thermoplastic; they differ from each other in terms of behavior 
during the IM process and characteristics of the finished products (Table 1) [1]. 
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Table 1: amorphous vs semi-crystalline thermoplastic polymers. 
 Amorphous Semi-Crystalline 
IM behavior 
soften on heating melt on heating 
poor lubricity good lubricity 
IM product 
characteristics 
limited and isotropic 
shrinkage 
marked and anisotropic 
shrinkage 
high impact strength low impact strength 
transparent opaque 
 
Because of the wide range of polymers available, the basic component can be chosen 
taking many different issues into account, such as the equipment, the time and costs of the 
process as well as the characteristics that the molded products should present depending of 
their final application. An improvement in the product characteristics may involve the use 
of extra components, sometimes very expensive and/or with critical processability. Hence, 
the formulation has to balance all aspects. In this respect, the most important categories of 
aids employed in the plastics industry are [3]: 
- fillers (e.g. talc; mica), used in order to decrease the percentage of thermoplastic 
polymer, thus reducing the overall costs; 
- reinforcements (e.g. graphite; glass fibers), generally added at 10-40% by weight to 
enhance properties such as mechanical strength and stiffness; 
- colorants, organic (e.g. phtalocyanine; diazos) or inorganic (e.g. iron oxides; carbon 
black); 
- agents limiting shrinkage and warpage (e.g. glass; carbon fibers); 
- substances that may impart specific properties such as electrical conductivity (e.g. 
nickel; steel); 
- plasticizers (e.g. dioctilphtalate for PVC) that improve the polymer melt flow index 
during the IM process/increase the product flexibility. 
In order to help the ejection of the finished item from the mold, it is sometimes necessary 
to use mold release agents. These can be included in the injected mixture (internal 
lubricants, e.g. erucic and stearic amides used at 0.1-1%) or simply be applied to the mold 
cavity surface (external lubricants, e.g. silicone oils). 
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When applying IM technique to drug delivery, the formulation step may especially be 
challenging. Indeed, strict quali-quantitative limitations can be associated with the need for 
ensuring the quality, efficacy and safety requisites of drug products. These limitations are 
primarily dictated by the dose, physico-chemical characteristics and stability profile of the 
active ingredient, which cannot be modified. In particular, the operating temperatures 
could cause drug degradation phenomena to occur in-process or impair the overall stability 
of the product. Further aspects, such as the release pattern pursued, the tolerability and 
pharmaceutical acceptability of all excipients as well as the possibility of undergoing 
sterilization, are also to be considered. 
The selected polymer is expected to fully or partly govern the release performance on the 
one hand, and possess on the other suitable melt flow index, thermal stability and behavior 
upon cooling. Moreover, depending on the design of the dosage form, certain challenging 
issues related to μIM might also be faced (e.g. injecting of minimal reproducible melting 
amounts). Indeed, microcomponents are defined as having typical exterior dimensions and 
wall thickness in the millimiter and micrometer ranges, respectively, as well as weight of 
hundred milligrams, which is consistent with values proper to drug products. Some other 
excipients may therefore need to be utilized in order to define not only the release pattern 
but also the processability of the polymeric component itself. 
The application of IM to the production of dosage forms is still limited, and rather simple 
formulations have been described in the literature thus far. With reference to the previously 
reported classification, the following aids only have been identified in IM pharmaceutical 
formulations: 
- reinforcements (e.g. microcrystalline cellulose, MCC; hydroxylapatite) [14,28]; 
- substances that may impart specific properties, added to modify the release 
performance (e.g. disintegrants; release modifiers; polymeric carriers for the 
formation of solid dispersions) [20-32]; 
- plasticizers used to lower the polymer glassy-rubbery transition temperature thus 
allowing the manufacturing process to be carried out at temperatures consistent 
with the drug and/or excipient stability (e.g. dibutyl sebacate, DBS; polyethylene 
glycol, PEG; glycerol) [28-33]. 
Excipients are often chosen based on literature data derived from techniques other than 
IM. For plasticizing purposes, for example, substances that are generally employed in film-
coating processes are selected. Besides, internal and external lubricants are those used in 
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tableting (e.g. stearyl alcohol) and in the preparation of lozenges (e.g. vegetable oils), 
respectively. 
By contrast, in some preliminary studies, silicone oils have been exploited as external 
lubricants, although these would be unsuitable for pharmaceutical use. 
 
4. Applications 
The exploitation of IM in the pharmaceutical area for the production of conventional 
dosage forms or Drug Delivery Systems (DDSs) is aimed at reducing the time and costs of 
manufacturing and/or improving the performance of drug products that are currently 
prepared by other techniques. Notably, only in a limited number of studies, actually 
innovative and unique design, composition and functional characteristics are described. 
This article takes into account systems reported in the primary scientific literature and 
purposely omits all potential applications of the IM technique described in patents, which 
would require a separate discussion because of the high number and wide variety. All types 
of IM application reviewed herein along with their key formulation and manufacturing 
characteristics are summarized in Table 2. 
 Table 2: IM applications reviewed and relevant characteristics. 
References Product Polymer Formulation aspects Equipment Application 
13, 16, 19, 
34, 36, 39-44 
Oral capsules 
Potato starch 
Gelatin 
Starch/water or gelatin/water 
mixtures (around 15% water 
content) 
Horizontal injection molding 
machine (screw type) 
Alternative system to 
gelatin dip-molded 
capsules 
14 IR tablets 
PEG 6000 
PEG 8000 
Drug: different active ingredients 
(dispersed/dissolved in the molten 
carrier) 
Reinforcement: MCC 
Horizontal injection molding 
machine (screw type) 
Alternative to 
immediate-release 
compressed tablets 
29-32, 47 
Oral non-
disintegrating 
matrices 
Wheat starch 
EC 
Drug: model active ingredient 
(sodium benzoate); metoprolol 
tartrate 
Plasticizer: glycerol, DBS 
Release modifier: HPMC, L-HPC, 
xanthan gum, PEO 
Reinforcement: MCC 
Mold release agent: silicon based spray 
(external) 
Horizontal injection molding 
machine (screw type) 
Twin-screw mini-extruder + lab-
scale vertical injection molder 
Alternative to 
compressed non 
disintegrating oral 
matrices 
15, 17, 21, 
48-51 
Implantable 
matrices 
PLA 
Polyanhydride 
copolymer 
PLC 
PLGA 
Drug: valpreotide pamoato, 
gentamicine sulfate, fluconazole, 
praziquantel, 5-fluorouracil 
Horizontal injection molding 
machine (screw type) 
Bench-top micro-molding machine 
(plunger type) 
Vertical injection molding machine 
Twin-screw mini-extruder + lab-
scale vertical injection molder 
Homemade equipment 
Alternative to current 
implants 
 
 
52, 53 
Intravaginal 
inserts 
PLC 
Ethylene vinyl 
acetate 
Drug: progesterone, davipirine 
Horizontal injection molding 
machine 
Twin-screw extruder + injection 
molder (hydraulic or plunger-type) 
Alternative to current 
intravaginal inserts 
54-63 
Oral multi-
layer device 
Impermeable 
shell: 
biodegradable 
polymers (e.g. 
EC) 
Plug/matrix: 
soluble/erodible 
polymers (e.g. 
PEO) 
Drug: carvedilole, opioids (e.g. 
hydrocodone, morphine) 
Plasticizers (shell): e.g. cetostearyl 
alcohol 
Not specified 
Double injected 
device for prolonged 
or pulsatile release 
28, 65 Bi-layer device 
Soy protein 
isolate 
Drug: theophylline 
Cross-linker: glyoxal 
Plasticizer: glycerol 
Reinforcement:  
hydroxyl apatite 
Twin-screw extruder + horizontal 
injection molding machine (screw 
type) 
Co-injected device for 
controlled release 
33, 72 
Oral capsular 
device 
HPC 
Plasticizer: PEG 1500 
Mold release agent: peanut oil 
(external) 
Bench-top micro-molding machine 
(plunger type) 
Functional container 
for pulsatile/colonic 
release 
73 
Oral magnetic 
depot capsular 
device 
PLC 
Polycaprolactam 
PLC/starch 
- Homemade equipment 
Magnetic driven 
container for site 
specific release 
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Dip-molding has extensively been used for the manufacturing of gelatin capsules for over a 
century and in this period it has undergone many improvements. However, it requires the use 
of 30% aqueous gelatin solutions maintained at 40 °C, which represent a good substrate for 
bacterial growth. Moreover, water needs to largely be removed by drying the molded items 
thus increasing the time and costs of production. Since the second half of the ‘90s, a 
thermoplastic processing technique for the molding of capsules was sought that would allow 
softened materials with a constant and low water content to be employed [16,19,34]. IM was 
therefore proposed also in view of the possibility of molding products with precise size, shape 
and closure characteristics. In addition, such a technique might be applied to materials that 
could not be processed by dip-molding. In this respect, starch was selected because it is a 
plant polymer that would overcome some common religious or dietary constraints and could 
especially be appealing for health (nutraceuticals) and food markets. Both gelatin and starch 
show a thermoplastic behavior under mechanical stress, in specific humidity and temperature 
conditions [34-38]. In particular, potato starch capsules with 0.4 mm wall thickness (Capill®) 
demonstrated an in vitro (disintegration time) and in vivo (bioavailability and scintigraphic data) 
performance comparable with that of marketed hard gelatin capsules [16,39]. Capill® was 
proposed in five different sizes (the same cap fits bodies with different lengths) and can easily 
be filled with a variety of formulations (solid or liquid) [40,41]. Generally, Capill® shell devices 
showed satisfactory technological characteristics in terms of dimension (height, length and 
wall thickness) consistency, suitable mechanical strength and smoothness of the surface. 
Capill®-based formulations were successfully proposed as the core for pH-sensitive coated 
DDSs [39,42]. In particular, by the Targit® technology [43,44], which relates to a starch 
capsule coated with a mixture of Eudragit® L and S up to different thicknesses, the authors 
claimed the possibility of targeting specific sites within the intestinal region (e.g. colon) through 
a combined pH- and time-dependent mechanism [45,46]. 
IM was also explored as an alternative technique for the preparation of conventional tablets 
[14] and oral prolonged-release matrix systems [29-32], implants [15,17,21,48-51] or 
intravaginal inserts [52,53], which are mostly manufactured by compression or HME at 
present. 
The production of tablets by IM was preliminarily evaluated using solid PEGs as 
thermoplastic polymeric carriers and MCC as the reinforcement agent for immediate-release 
(IR) formulations [14]. The process was demonstrated to provide significant benefits, such as 
dust containment, good content uniformity even with low-dosed active compounds (< 1%) 
and poor influence of the particle size and shape of the drug on the physical properties of the 
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tablets. Stability and loading limitations, connected with the drug solubility in the molten 
polymer, were in few cases observed. According to the authors, although the estimated 
manufacturing rates would be lower than with conventional tableting, this might be 
outweighed by the reduced time, steps and costs needed to reach an industrial-scale 
production and by the continuous nature of the IM process. 
Moreover, IM technique offers several possible advantages in the development of non-
disintegrating prolonged-release drug delivery systems, such as the homogeneous embedding 
of drug particles within release-controlling polymer combined with the ability to yield and 
accurately define any possible shape of the device (e.g. round-shaped end to facilitate 
subcutaneous implantation [48]). With respect to biodegradable implants, the temperature 
conditions required by IM could be sufficient to sterilize the substrate material 
(autosterilization) with no need for other procedures that might alter the chemical and 
mechanical characteristics of the final product (e.g. γ-sterilization, ethylene oxide) [21]. Among 
prolonged-release DDSs, those produced by IM generally ensure a low porosity, great ability 
to maintain physical integrity (no disintegration/break) and effective control of release (very 
slow release rates obtained). 
The use of wheat starch as the matrix former for oral prolonged DDSs was explored based on 
the thermoplastic properties shown by potato starch that were formerly exploited by the 
Capill® technology [47]. Ethylcellulose (EC) IM matrices, containing different hydrophilic 
polymers as release promoters, e.g. hydroxypropyl methylcellulose (HPMC) [29], low-
substituted hydroxypropyl cellulose (L-HPC) [30], polyethylene oxide (PEO) [31] and xanthan 
gum [32], were also developed. 
According to the their well-known thermoplasticity, some polymers were used to prepare 
biodegradable IM implants such as poly(L-lactide) (PLA) [21,48,49,51], poly(L-lactide-co-
glycolide) copolymers (PLGA) [51], poly(ε-caprolactone) (PLC) [50]. Furthermore, a 
polyanhydride-based implantable system containing gentamicin sulfate for the treatment of 
osteomyelitis (Septacin™) was designed in the form of a string of five beads joined by four 
linkers having the same composition as the beads, and the relevant production-scale 
manufacturing was developed. In vivo data from infected animal models (rats and horses) 
demonstrated the ability of the implant to eradicate specific bacteria (Staphylococcus aureus) 
[15]. Moreover, a tolerability study conducted with surgically-treated patients showed that 
Septacin™ could provide high local drug concentrations at the implantation site while limiting 
the systemic levels. 
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As already mentioned, only a few applications of IM relate to delivery systems actually 
innovative in terms of design, composition and/or performance. In this respect, Egalet® is a 
new delivery platform for oral administration able to ensure a prolonged or pulsatile/delayed 
release of active substances [54-59]. 
In the prolonged-release configuration, this system is composed of a drug-containing 
hydrophilic/erodible matrix partially coated with an insoluble and impermeable polymeric 
layer (Figure 3a). The drug liberation can only occur from the two uncoated lateral surfaces 
and is driven by a diffusion/erosion-based mechanism. The release rate control (zero-order 
kinetics) is achieved by a restriction of the area in contact with aqueous biological fluids. By 
adding two erodible polymeric plugs at each open end, a lag phase prior to release can be 
obtained (Figure 3b). The duration of such a delay period can be modulated depending on the 
composition and thickness of the plugs. An active ingredient could also be included in the 
formulation of these plugs, thus enabling a repeated release of the same drug or distinct 
release pulses of different drugs (multi-therapy platform). 
 
 
Figure 3: outline and expected release profiles of Egalet® [59]. 
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The ability of the Egalet® technology to achieve zero-order release or selective delivery to the 
colonic region was demonstrated by γ-scintigraphic and pharmacokinetic studies [56,57,60]. In 
particular, the Egalet® ADPREM (Abuse Deterrent Prolonged Release Erodible Matrix) 
technology was developed for the administration of opioids (e.g. morphine; hydrocodone) to 
reduce the daily dosing frequency in patients under pain management therapy thus involving a 
lower risk of abuse [61,62]. 
The Egalet® release platforms are based on well-known materials, design and release 
mechanisms, yet they take advantage of IM for the preparation of multi-layer delivery systems 
within a single process (Egalet® technology). Such a process involves two subsequent injection 
phases into the same mold from two perpendicularly-positioned nozzles [63]. During the 
former phase, a plunger is placed in the center of the mold cavity, creating a gap between its 
own surface and the wall of the cavity. The coating material is injected into this space by the 
vertical nozzle and, as soon as it has cooled down, the plunger moves back. At the same time, 
the latter injection of the drug-containing core formulation is run. Finally, the plunger returns 
to the first injection position, thus favoring the ejection of the molded device. 
By an innovative co-injection technique, Vaz and co-authors proposed a bi-layer delivery 
system based on soy protein [28,64,65]. This technique represents an evolution of traditional 
IM and likewise derives from the plastics industry where it was employed for the 
manufacturing of devices with a well-defined geometry and skin/core morphology [66]. It 
entails the sequential injection into the mold of skin and core materials from two different 
plasticating chambers through the same runner (Figure 4). This technique allows the core 
aterial to be completely encapsulated thus being potentially advantageous for the preparation 
of coated systems. 
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Figure 4: outline of a co-injection process [66]. 
 
Besides the general advantages offered by IM in terms of cost-effectiveness and industrial 
scalability, co-injection enables the simultaneous use of different materials to achieve a coated 
device in a one-step process without requiring further operations. Moreover, the coat layer 
thickness can precisely be defined irrespective of different shape characteristics. With respect 
to the release performance, the authors claimed the possibility of controlling the drug 
liberation by modulating the skin thickness and the cross-linking degree of the matrix-forming 
soy protein. In order to enhance the release control options, multi-layer systems could also be 
devised. 
In the field of oral DDSs, the Chronotopic™ is a swellable/erodible device for pulsatile 
and/or time-dependent colonic release based on hydrophilic cellulose derivatives [67-71]. The 
duration of the lag phase prior to release depends on the thickness and composition of the 
functional cellulosic barrier applied to the drug-containing core. By pharmacokinetic and γ-
scintigraphic studies, the Chronotopic™ was proved able to provide lag phases consistent 
with chronotherapy and colon targeting purposes. By employing the IM technique, a different 
configuration of the system was proposed based on separate container shells and drug fillings 
[33]. Such a shell device (Chronocap™) thus represents a functional container intended to 
convey differing formulations and release a variety of bioactive compounds following 
programmed lag phases. The peculiar advantages of the Chronocap™ would lie in the 
24 
possibility of undergoing an independent pharmaceutical development regardless of the final 
contents and the scalability of the relevant manufacturing process. Capsular shells with 
nominal thicknesses of 300, 600, 900 μm prepared from various hydroxypropyl cellulose 
(HPC) grades exhibited satisfactory technological properties and performance (Figure 5, Table 
3). In particular, mechanical resistance was demonstrated to be comparable with that of hard 
gelatin capsules or even higher. Capsule shells filled with a tracer drug formulation showed 
reproducible in vitro lag phases followed by an immediate drug release caused by breakage of 
the shell. Lag times were dependent on the HPC grade and the shell wall thickness. In a 
preliminary in vivo evaluation, Klucel® LF-based systems were proved to yield delayed salivary 
levels of the conveyed model drug as a function of the shell thickness, with a linear correlation 
between in vivo and in vitro lag times [72]. 
 
 
Figure 5: Klucel® LF-based Chronocap™ devices: (a) cap and body, (b) bodies with differing nominal 
thicknesses (300, 600 and 900 μm) and (c) morphological changes in aqueous fluid [33]. 
 
Table 3: key characteristics of Klucel® LF-based Chronocap™ devices with differing nominal 
thicknesses [33] and [72]. 
Nominal thickness 
μm 
Thickness  
μm (CV) 
Elastic modulus 
N/mm2 (CV) 
t10% in vitro 
min (CV) 
t10% in vivo 
min (CV) 
300 346 (12.30) 2.672 (15.04) 29.3 (22.2) 75.0 (13.6) 
600 645 (13.20) 5.342 (15.72) 53.5 (10.6) 140.4 (16.2) 
900 880 (4.64) 8.451 (3.44) 91.7 (3.16) 211.8 (20.1)  
 
Polymeric capsules prepared by IM, the gastrointestinal (GI) transit of which would be 
externally controlled by means of a magnet, were also proposed [73]. Thanks to a small 
magnet placed inside the capsule, the system can be maintained in a specific site (e.g. the 
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stomach) for a defined period of time and, only after removing the external control magnet 
positioned on the skin in the concerned area, it can move on. The ability of magnetic depot 
preparations to increase the gastric residence time of solid dosage forms thus improving the 
bioavailability of drugs poorly absorbed in the lower parts of the GI tract was explored in 
animals and in humans using systems obtained by tableting or by filling commercially available 
capsules [74-76]. The use of IM allowed capsule-like shells with the magnet already inserted to 
be manufactured, and polymers with lower environmental impact to be screened. 
 
5. Conclusions 
In the present work, conventional and controlled-release dosage forms prepared by IM are 
reviewed. As it enables the manufacturing of 3D-shaped objects (monolithic, multilayer or 
coated ones) starting from polymeric formulations through a cyclic, automated process, this 
technique holds promise in terms of versatility (shape, dimensions, design and composition), 
patentability and industrial scalability of the obtained products. However, it may entail 
limitations related to the thermal stability of drug substances. 
The overview of the scientific literature and of the drug products developed has pointed out 
two main fields for the application of IM, i.e. its use as an alternative manufacturing technique 
due to inherent economic advantages, and exploitation as a viable approach to novel DDSs. 
Moreover, it has been highlighted that there still is a great potential for capitalizing on this 
technique especially with regard to areas where new concepts are required, such as primarily 
the development of actively controlled miniaturized devices or biological electromechanical 
systems (BioMEMS) [77-80]. 
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GASTRORESISTANT CAPSULAR DEVICE PREPARED BY INJECTION MOLDING 
 
Abstract 
In the present work, the possibility of manufacturing by injection molding (IM) a gastro-
resistant capsular device based on hydroxypropyl methyl cellulose acetate succinate 
(HPMCAS) was investigated. By performing as an enteric soluble container, such a device 
may provide a basis for the development of advantageous alternatives to coated dosage 
forms. Preliminarily, the processability of the selected thermoplastic polymer was 
evaluated, and the need for a plasticizer (polyethylene glycol 1500) in order to 
counterbalance the glassy nature of the molded items was assessed. However, some critical 
issues related to the physical/mechanical stability (shrinkage and warpage) and opening 
time of the device after the pH change were highlighted. Accordingly, an in-depth 
formulation study was carried out taking into account differing release modifiers potentially 
useful for enhancing the dissolution/disintegration rate of the capsular device at intestinal 
pH values. Capsule prototypes with thickness of 600 and 900 µm containing Kollicoat® IR 
and/or Explotab® CLV could be manufactured, and a promising performance was 
achieved with appropriate gastric resistance in pH 1.2 medium and break-up in pH 6.8 
within 1 h. These results would support the design of a dedicated mold for the 
development of a scalable manufacturing process. 
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1. Introduction 
Preventing the chemical degradation of active principles in the acidic environment of the 
stomach and protecting the gastric mucosa from irritation phenomena induced by drug 
assumption are the two main reasons for conceiving gastro-resistant dosage forms [1]. Such 
formulations are also used to pursue selective release into particular regions of the intestinal 
tract, either to exploit favorable absorption sites or provide treatment for local diseases. 
Moreover, according to a time-dependent strategy, the colon can be targeted by enteric-
coated pulsatile delivery systems able to provide lag phases starting on gastric emptying, 
with the coating dissolution, and lasting throughout the small intestinal transit time (SITT) 
[2-4]. 
Gastric resistance is generally obtained by means of polymers with pH-dependent 
solubility; the most widely employed are acrylic and metacrylic acid copolymers (e.g. 
Eudragit® L, S and FS), polyvinyl acetate phthalate (PVAP) and cellulose derivatives (e.g. 
cellulose acetate phthalate, CAP; hydroxypropyl methyl cellulose acetate succinate, 
HPMCAS) [5]. These are applied onto drug-containing solid cores (tablets, capsules, 
pellets, granules) using different techniques that can basically be distinguished according to 
the amount of solvent required, preferably water, and the role it would play in the coating 
process. Large amounts of liquid to be dried are in fact involved in the deposition of 
gastro-resistant layers from polymeric solutions or suspensions (film-coating technique) [6-
9]. On the other hand, in order to avoid the use of water thus overcoming stability issues 
and drawbacks associated with the need for solvent removal, dry-coating techniques were 
proposed, such as conventional compaction-based processes (press-coating technique) [10-
13]. More sophisticated approaches envisage the deposition onto core substrates of liquid 
(non-aqueous) or solid (powder blends) coating agents, and subsequent formation of a 
continuous layer by solidification/polymerization or heat-curing [14-17]. Despite the 
improvements in terms of process time, manufacturing costs and stability of the final 
product, the industrial scale-up and availability of suitable coat-forming agents still 
represent major limitations to a wider diffusion of dry-coating techniques. 
In the case of enteric-coated products intended to release the active ingredient as soon as 
they are emptied from the stomach, a rapid disintegration/dissolution of the coating layer 
is expected. This is especially important when drugs having an absorption window in the 
upper part of the small intestine are dealt with [18]. It was recently highlighted that gastro-
resistant systems can take up to 2 h for a complete exposure of the core to the intestinal 
fluids, thus potentially affecting the drug bioavailability and the efficacy of the therapy [19]. 
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In coating processes an important role is generally played by the drug-containing core, the 
physical (shape, dimension, surface), technological (thermal resistance, hardness, friability, 
wettability, disintegration/dissolution tendency) and stability characteristics of which may 
constrain or even impair each of the above-mentioned techniques [20-23]. 
Based on the above-discussed premises, the possibility of preparing container-like enteric-
soluble devices that could be filled and sealed after manufacturing would represent an 
innovative and advantageous alternative to the design of coated gastro-resistant dosage 
forms. In this respect, hollow HPMCAS or PVAP pipes were prepared by hot melt 
extrusion, manually filled with a model drug powder and heat-sealed at their open ends, 
thus providing enteric devices that showed promising results [24]. 
Injection molding (IM), which involves the injection of appropriately softened/melted 
materials into a mold wherein they are given a definite three-dimensional shape, was 
proven a viable technique in the preparation of capsular items composed of separately 
manufactured parts to be matched after filling with various formulations (powders, 
granules/pellets, semi-solids or liquids) through well-established processes [25]. The 
performance of such devices would depend on their composition and design features 
(morphology and thickness of the shell) only, in spite of differing characteristics of the 
conveyed drug and/or formulation, which could offer major benefits in terms of time and 
costs required for development. Moreover, they would be ready-to-use, i.e. easy to be filled 
for extemporaneous preparations. Molded capsular shells composed of potato starch 
(Capill®) were proposed to replace commercial gelatin or hydroxypropyl methyl cellulose 
capsules intended for immediate release (IR) [26,27]. More recently, IM was successfully 
employed to prepare a capsular pulsatile delivery device based on swellable/erodible 
polymers (hydroxypropyl cellulose, HPC) [28-30]. 
In the present work, the feasibility of IM in the preparation of HPMCAS-based capsules 
was explored with the aim of developing a gastro-resistant shell to be used as an innovative 
delivery platform for enteric dosage forms. 
 
2. Materials and methods 
2.1. Materials 
Hydroxypropyl methyl cellulose acetate succinate (HPMCAS, AQUOT-LG®; Shin-Etsu, J); 
polyethylene glycol (PEG 1500; Clariant Masterbatches, I); sodium starch glycolate 
(Explotab® CLV; JRS, D) (d10 = 10 µm; d50 = 25 µm; d90 = 52 µm); polyvinyl alcohol-
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polyethylene glycol graft copolymer (Kollicoat® IR; BASF, D) (d10 = 9 µm; d50 = 23 µm; d90 
= 55 µm); dipotassium hydrogen phosphate anhydrous (K2HPO4; Carlo Erba, I) (d10 = 2 
µm; d50 = 6 µm; d90 = 24 µm); sodium hydrogen carbonate (NaHCO3; Carlo Erba, I) (d10 = 
15 µm; d50 = 28 µm; d90 = 63 µm); acetaminophen (Atabay, TR) (d10 = 14 µm; d50 = 29 µm; 
d90 = 58 µm). 
 
2.2. Methods 
2.2.1. IM process 
IM was performed by a bench-top micromolding machine (BabyPlast 6/10P, Cronoplast 
S.L.; Rambaldi S.r.l., I). 
The polymeric formulations were prepared by co-grinding HPMCAS and PEG 1500 in a 
blade mill; blends containing release modifiers were obtained by mixing in turbula (Type 
T2C, WAB, CH) for 20 min. Prior to use, all materials except for PEG 1500 were kept in a 
ventilated oven at 40 °C for 24 h. In Table 1 the composition (%, by weight) of the molded 
polymeric formulations is reported. 
 
Table 1: composition (% by weight) of molded formulations. 
 Polymer Plasticizer Release modifier 
Code HPMCAS PEG 1500 Explotab®CLV Kollicoat®IR 
PEG15 87 13 - - 
PEG25 80 20 - - 
PEG35 74 26 - - 
EXP 60 15 25 - 
EXPPEG35 55 20 25 - 
KIR 60 15 - 25 
1EXP2KIR 60 15 8.5 16.5 
2EXP1KIR 60 15 16.5 8.5 
 
Before processing, the behavior of the polymer and polymeric formulations when 
subjected to heating or IM was evaluated as follows. 
Hot-plate experiment: 2-3 g of polymer/polymeric formulation was placed in an aluminum 
pan on a hot plate and heated under continuous manual mixing, while gradually increasing 
the temperature up to 200 °C. Samples were checked for overall aspect, color, texture and 
mechanical characteristics during heating and after cooling. 
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Air shot test: 50 g of polymer/polymeric formulation was loaded into the IM press through 
the hopper and expelled from the injecting unit as during a purge operation [31]. The test 
was repeated under different operating temperatures. Samples were checked for overall 
aspect, color and mechanical characteristics immediately after ejection and when solidified. 
 
2.2.1.1. Manufacturing of molded items 
50 g of polymeric formulation was loaded into the plasticating chamber of the IM press 
through the hopper and then conveyed by means of a first piston to the injecting chamber. 
By successively applying two distinct pressures, each for a defined period of time and at a 
selected rate, another piston (10 mm diameter) injected a specific amount of melt (charge) 
through a 1 mm diameter nozzle into the mold cavity (disk or capsular shape). Prior to 
product ejection, the mold was kept closed by applying a closing pressure to allow the 
injected melt to cool down and harden. The rate of each process stage was expressed as % 
of the maximum value. 
Molded items were prepared by means of two different molds: i) a 30 mm diameter disk-
shaped mold provided with a central gate, enabling the selection of differing thicknesses 
(200, 400, and 600 µm) and ii) a capsular mold with two cavities for the cap (8 mm height 
and 8 mm diameter) and the body (11 mm height and 8 mm diameter), respectively, each 
provided with a lateral gate, enabling the preparation of matching items within a single 
manufacturing cycle and the selection of differing shell thicknesses (300, 600, and 900 µm) 
[29]. The operating conditions were varied within different ranges of values according to 
whether disks or capsules were employed (Table 2). Molds were manually lubricated with 
peanut oil approximately every 15-20 units manufactured. The first unit obtained after this 
operation was discarded. 
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Table 2: IM operating conditions. 
 Disk Capsule 
 
  
Plasticating chamber temperature, °C 120-160 140-165 
Injecting temperature, °C 130-170 143-168 
Nozzle temperature, °C 140-180 145-170 
Charge, mm 4.5-11 6-20 
First-injection pressure, bar 20-90 60-110 
First-injection time, s 0.8 0.8-20 
First-injection rate, % 40-90 5-85 
Second-injection pressure, bar 15-70 35-65 
Second-injection time, s 0.3 0.3-10 
Second-injection rate, % 30-70 40-75 
Cooling temperature, °C 15 15-25 
Cooling time, s 2.5 10 
Closing pressure, bar 60 60-90 
Opening rate, % 20-40 40 
 
2.2.2. Characterization of molded items 
Molded items, i.e. disks and assembled capsule shells, were checked for weight (analytical 
balance BP211, Sartorius, D; n = 10) and thickness (digimatic indicator ID-C112X, 
Mitutoyo, J; n = 10). Digital photographs (Nikon D70, Nikon, J) of molded items were 
acquired, and photomicrographs were taken by scanning electron microscope (SEM; 
Sigma, Zeiss, D) after gold sputtering (10 nm). The characterization was performed 
immediately after ejection, except for photomicrographs, and after 24 h storage at ambient 
conditions (24 ± 2 °C/55 ± 5% RH). Photomicrographs of a few molded disks were also 
collected after incubation in unstirred pH 6.8 phosphate buffer at room temperature for 
120 min and drying in a ventilated oven at 40 ◦C for 24 h. 
 
2.2.2.1. Evaluation of gastric resistance performance 
Disks: immediately after ejection disks were positioned on manually assembled cells 
modified from the extraction cells used in the dissolution test for transdermal patches (Ph. 
Eur. 7th ed.) (Figure 1). The reservoir compartment was loaded with an amount of a 
powder tracer (acetaminophen) ranging from 43 to 48 mg. The surface exposed to the 
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acceptor fluid was 177 mm2. The test (n = 3) was performed in pharmacopoeial apparatus 2 
(Dissolution System 2100B, Distek, US) at 100 rpm under the conditions of the 
Dissolution test for delayed-release dosage forms (Method B, USP 34) except for the 
medium volume (600 mL). Fluid samples were withdrawn at fixed time points and assayed 
spectrophotometrically at 254 nm (spectrophotometer lambda25, Perkin Elmer, US). 
 
 
Figure 1: outline of the system for the evaluation of disk gastric resistance. 
 
Capsular devices: each capsule body was manually filled with an amount of a powder tracer 
(acetaminophen) ranging from 86 to 92 mg and closed with a matching cap. The gastric 
resistance performance (n = 3) was evaluated in pharmacopoeial apparatus 2 (Dissolution 
System 2100B, Distek, US) at 100 rpm under the conditions of the Dissolution test for 
delayed-release dosage forms (Method B, USP 34). Fluid samples were withdrawn and 
assayed as above reported. Lag time (t10%), i.e. the time to 10% release in pH 6.8 phosphate 
buffer, was calculated from the release curves (n = 3) and reported as a detail in the figures 
together with the relevant coefficient of variation (CV). 
 
3. Results and discussion 
With the aim of developing a new injection-molded capsule-like container for enteric 
release, the relevant design and formulation features needed to preliminarily be assessed. 
The latter were indeed expected to fulfill a number of different requirements, such as the 
suitability for the oral route, versatility in terms of contents and possibility of filling 
through established industrial encapsulation processes. At the same time, the desired gastric 
resistance performance followed by a rapid disintegration/dissolution at intestinal pH 
values had to be ensured and merely depend upon the container device irrespective of the 
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conveyed formulation. Furthermore, the IM process should have been feasible and yield 
molded items with appropriate aspect, technological properties and physical/mechanical 
stability. As in the micromolding (µIM) technique, which is currently applied to the 
production of medical devices and miniaturized electronic parts, a specially devised press 
had to be employed, and the manufacturing was expected to be particularly critical in view 
of the need for meeting strictly controlled geometric as well as functional characteristics 
and maintain them over the shelf-life of the final formulation [32-37]. Besides, a strong 
impact of the operating pressure and thermal history of the material on the dimensional 
stability of the molded item had to be taken into account. 
HPMCAS was chosen as the barrier-forming polymer because of its wide application as an 
enteric coating material and thermoplastic properties that were already exploited for hot 
melt extrusion (HME) [24]. Preliminarily, its softening/melting behavior following heating 
on hot plate or injection processing (air shot test) and its characteristics after solidification 
were evaluated, indicating the need for the addition of a plasticizer in order to counteract 
the glassy nature of the molded material. Among various plasticizers tested (triethyl citrate; 
dibuthyl sebacate; PEG 400, 1500, 6000 and 20000), PEG 1500 was selected based on the 
homogeneous aspect of the softened/molten raw materials and the improved mechanical 
characteristics of the solidified composite. Moreover, HPMCAS blends with PEG 1500 
turned out to be the most easily processed by the IM press in use. The influence of the 
plasticizer on the processability of the polymeric formulation and the characteristics of the 
product was investigated in the 15-35% (with respect to the amount of polymer) range by 
means of two differing molds, i.e. a disk- and a capsule-shaped one, each allowing the 
nominal thickness of molded items to be varied within a relatively wide range (600, 400 and 
200 µm or 900, 600 and 300 µm, respectively). The former allows the production of 
centrally gated circular disks (diameter 30 mm) especially suitable for the evaluation of 
dimensional changes. With respect to the capsule-shaped mold, though offering several 
advantages (i.e. production of capsule cap and body within the same cycle, possibility of 
varying the shell thickness), some limitations in the characteristics of the resulting items 
could be expected in view of the lateral position of the gate and presence of a mobile insert 
determining the width of the cavity [29]. 
The amount of 15% of plasticizer turned out to be insufficient, not only on account of the 
poor flexibility shown by the molded items, but also because only 600 µm thick disks could 
be obtained and no capsular shells at all. Increasing the PEG 1500 content to 25% was 
already enough to easily manufacture disks up to 200 µm thickness and complete capsular 
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shells of 900 µm. Only with the highest amount of plasticizer tested, 600 µm capsules could 
be prepared. 
When thermoplastics are processed by IM, the dimensions of the molded part change as 
the part cools. Often, these changes are referred to as either shrinkage or warpage and can 
be used to predict the appropriate mold geometry [38]. Although shrinkage is based on 
thermal contraction, other mechanisms may be responsible for dimensional changes after 
demolding (e.g. inherent stresses, crystallization, mechanical constraint). For example, if 
residual stresses created by variations in the cooling rate are strong enough to overcome 
the relevant structural integrity, the part will warp upon ejection from the mold. The 
control of shrinkage is particularly important in applications requiring tight tolerances. The 
wall thickness was shown to have a major influence on shrinkage that generally turns out 
increased for thicker parts, because of the variation in a series of parameters such as the 
holding pressure or the cooling and crystallization rates. In Table 3, differences between 
the thickness of disks and the width of the relevant mold cavity (600 µm) are reported 
along with digital photographs of the molded items immediately after ejection (t = 0) and 
over time (t = 3 and 24 h). 
Molded HPMCAS disks were proven to increase in thickness immediately after demolding, 
and no significant influence (p < 0.1) of the amount of plasticizer on this parameter was 
found. On the contrary, a warp tendency of molded disks was noticed that could be related 
to the amount of plasticizer in the formulation. In fact, only for the items containing 15% 
of PEG 1500, bending was neither observed following demolding nor after storage. This 
allowed thickness measurements to be performed also 24 h after manufacturing. 
 
Table 3: changes in thickness and aspect of 600 µm disks over 24 h from manufacturing. 
Code 
Δ thickness 
µm (CV) 
 
t = 0 t = 24 h t = 0 t = 3 h t = 24 h 
PEG 15 43 (7) 47 (8) 
   
PEG 25 55 (23) nd 
   
PEG 35 35 (21) nd 
   
nd = not determined because of disk deformation; scale bar           = 5 mm 
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As far as the gastric resistance of PEG25 and PEG35 formulations is concerned, the 
relevant capsular devices, irrespective of the shell thickness, remained intact in acidic fluid 
(pH 1.2) but they were unable to release their contents within 2 h in phosphate buffer pH 
6.8. 
These results pointed out some critical issues with respect to the goal of developing a 
delivery platform for enteric dosage forms based on HPMCAS capsules. In particular, the 
shrinkage/warpage tendency of the polymeric formulation and the need to shorten the 
opening time of the device had both to be taken into account. In the plastics industry, for 
the development of molded items, the design of a mold and the set-up of the melt 
composition as well as of the operating conditions would concomitantly be performed by 
trial and error once their requirements are defined (Figure 2). However, the inherent 
complexity of this approach would further be increased in the case of pharmaceutical 
products due to the need for fulfilling challenging requirements, such as a defined release 
behavior, and to the limited information available on the IM processability of the 
excipients involved (polymer and adjuvants). At this stage, it was accordingly decided to 
focus on a formulation study, and molded prototypes were used as screening tools for 
assessing the effectiveness of the gastric resistance performance. The thermal and 
rheological characteristics as well as mechanical stability of the selected formulation(s) will 
subsequently be evaluated in order to design the final mold. 
 
 
Figure 2: interrelated steps involved in the development of the molded device. 
 
With the aim of enhancing the dissolution/disintegration rate of the capsular device at 
intestinal pH values, i) release modifiers, the channeling action of which could be attributed 
to the inherent solubility or swelling properties, and ii) buffering salts (dipotassium 
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hydrogen phosphate and sodium hydrogen carbonate), potentially suitable for increasing 
the microenvironmental pH of the surrounding fluids, were considered. The addition of 
soluble pore formers or disintegrants (e.g. polyvinylpyrrolidone and croscarmellose sodium, 
respectively) to film-coating suspensions of pH-responsive polymers was already suggested 
with the aim of improving the pulsatile release of drugs to the ileo-colonic region [39,40]. 
Moreover, a double coated enteric system consisting of an inner layer of Eudragit® L or S 
neutralized with organic acids and an outer conventional coating of the same polymer was 
recently proposed [18,41,42]. Such a device was subject to a fast and consistent 
disintegration after stomach emptying (around 30 min in vivo disintegration time). 
The types and/or amounts of adjuvants were selected by preliminary heating and/or 
molding tests. In this respect, browning phenomena occurred at operating temperatures on 
polymeric samples containing either the phosphate or carbonate salt, thus pointing out 
possible stability issues for molded items. A polyvinyl alcohol-polyethylene glycol graft 
copolymer (Kollicoat® IR), generally employed as the film-forming polymer for immediate 
release coated dosage forms or as a binder in fast-dissolving tablets, was selected as the 
soluble pore former. Although characterized by a glassy-rubbery transition temperature (Tg) 
around 200 °C, when Kollicoat® IR was worked in admixture with plasticized HPMCAS, a 
homogeneous molded material was obtained already at the lowest operating temperatures. 
Among the disintegrants tested (starch and cellulose derivatives), sodium starch glycolate 
(Explotab® CLV) was shown to exert no negative impact on the processability of the 
polymeric substrate and rather improve the dimensional stability of molded items as 
expected from solid fillers [43]. As far as the polymer/plasticizer ratio in the polymeric 
formulations with the release modifiers is concerned, 25% of PEG 1500 with respect to the 
amount of HPMCAS was preferred because of the acceptable balance between 
processability of the polymeric substrate and dimensional changes of the product that was 
previously obtained. 
Disks of 200, 400 and 600 µm containing 30% by weight of either the soluble pore former 
or the disintegrant selected were obtained, whereas in no case intact and complete capsular 
shells with thickness other than 900 µm were produced. The manufacturing of 200 µm 
disks with the KIR formulation was especially critical, thus providing brittle and often 
damaged items that could not withstand characterization. SEM photomicrographs helped 
highlight the surface and structure characteristics of molded items containing Kollicoat® IR 
or Explotab® CLV as compared with HPMCAS ones (Figure 3). In particular, solid 
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particles distributed throughout the cross-section of the disintegrant-containing item are 
clearly evident. 
 
 
Figure 3: photomicrographs of the surface (a, b and c) and cross-section (at , bt and ct) of molded 
HPMCAS-based 400 µm disks, as such (a and at) or containing 30% by weight of a release modifier 
(Kollicoat® IR: b and bt or Explotab® CLV: c and ct). 
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In Figure 4 the release profiles of capsular devices containing a powder tracer and the 
relevant t10% values in pH 6.8 buffer are reported. 
 
 
Figure 4: release profiles of 900 µm thick enteric capsular devices containing 30% by weight of a 
release modifier (top: Kollicoat® IR, bottom: Explotab® CLV); mean t10% (min) in pH 6.8 buffer 
and relevant CV highlighted in tables. 
 
Both the Kollicoat® IR- and Explotab® CLV-based capsular systems were demonstrated 
able to withstand the acidic medium (pH 1.2) for 2 h, confirming that the release modifiers 
were efficiently embedded in the molded polymeric matrix. In pH 6.8 buffer a lag time of 
about 1.5 h prior to the break-up of capsular devices and release of the conveyed powder 
was observed, which was slightly shorter for the disintegrant-containing shell. Indeed, a 
minor diffusive release phase was shown by the capsular system with the soluble pore 
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former. In order to evaluate the influence of the polymeric barrier thickness, the molded 
disks made of HPMCAS blends with Kollicoat® IR and Explotab® CLV were used. For 
this purpose, a testing method analogous to the compendial dissolution test for transdermal 
patches was set up. The amount of tracer assayed in the acceptor fluid, which was 
separated from the donor powder reservoir by molded disks of differing thicknesses 
(Figure 1), was plotted versus time (Figure 5). 
As in the release profiles of capsules, a lag time prior to the rupture of the polymeric 
barrier was observed. Only in the case of the EXP formulation, t10% values showed a 
tendency to decrease when reducing the thickness of disks to 200 µm. Indeed, a small 
amount of tracer was recovered in the acidic medium when one of the 200 µm disks was 
tested thus pointing out the possible existence of a thickness threshold for gastric 
resistance failure. The polymeric barrier containing Kollicoat® IR confirmed a less prompt 
break-up, with an initial diffusive release phase. Moreover, in the case of 400 µm disks, t10% 
values obtained from the disintegrant-containing formulation were significantly (p < 0.1) 
lower as compared with those relevant to the KIR one, thus indicating that a more efficient 
mechanism would promote the polymer disintegration/dissolution in pH 6.8 buffer. The 
overall results obtained from capsular devices and disks containing pore formers indicated 
that the erosion of the HPMCAS matrix would in any case be triggered by the pH change, 
as this allows the medium to reach the adjuvants incorporated. Afterwards, the soluble 
polymer Kollicoat® IR may aid the solvent penetration only, while the disintegrant could 
also promote the formation of cracks in the polymeric barrier thereby reducing its 
resistance to rupture [40]. The latter hypothesis was confirmed by photomicrographs of 
partially eroded molded items (i.e. disks exposed to pH 6.8 buffer for 120 min and dried 
before being analyzed) (Figure 6). In fact, the disintegrant particles embedded in the 
polymeric matrix seem to be located within hollows that are larger than the dried particle 
itself and show tears on their edges. Such hollows and relevant tears may have formed 
because of the swelling of Explotab® CLV upon exposure to the aqueous fluid. 
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Figure 5: amount (%) of tracer in the acceptor fluid separated from the donor compartment by 
molded HPMCAS disks of differing thicknesses (600, 400 and 200 µm for a, b and c, respectively) 
containing 30% by weight of a release modifier (Kollicoat® IR on the left and Explotab® CLV on 
the right) versus time profiles; mean t10% (min) in pH 6.8 buffer and relevant CV highlighted in 
tables. 
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Figure 6: photomicrographs at different magnification (110, 400, 800, 2000x for a, b, c, and ct , 
respectively) of the surface of HPMCAS-based 400 µm disks containing 30% of Explotab® CLV 
after exposure to pH 6.8 buffer; ct is a detail from photomicrograph c. 
 
According to the above discussed mechanisms, the ability of the soluble pore former to 
increase the extent of solvent penetration could improve the efficiency of the disintegrant. 
In this respect, confirmatory results were preliminarily obtained comparing the 
performance of 900 µm thick capsular shells containing blends of Kollicoat® IR and 
Explotab® CLV (10% and 20%, respectively, and vice versa) (Figure 7) with that of shells 
based on a single component (Kollicoat® IR or Explotab® CLV). Indeed, devices prepared 
from the 2EXP1KIR formulation in which 10% of the disintegrant was replaced with the 
soluble polymer showed the shortest lag time. On the contrary, only 10% of disintegrant in 
the shell composition seemed not enough to establish the cracking mechanism. 
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Figure 7: release profiles of 900 µm thick enteric capsular devices containing 30% by weight of a 
mixture of release modifiers (top: 10% Explotab® CLV and 20% Kollicoat® IR, bottom: 20% 
Explotab® CLV and 10% Kollicoat® IR); mean t10% (min) in pH 6.8 buffer and relevant CV 
highlighted in tables. 
 
In order to undertake the development of gastric resistant container-like devices, the 
impact of the shell thickness on the release performance needed to be more in-depth 
investigated. Therefore, some attempts were made at improving the IM processability of 
adjuvant-containing HPMCAS formulations. As expected, by adjusting the polymer to 
plasticizer ratio (increasing the amount of PEG 1500 to 35% on dry polymer), thinner 
capsular shells of 600 µm were manufactured containing 30% of Explotab® CLV. The 
relevant devices showed adequate resistance in the acidic medium and, in pH 6.8 buffer, a 
lag phase of less than 1 h, i.e. reduced of approximately 40% as compared with that 
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provided by thicker capsules containing the same amount of Explotab® CLV (Figure 8). 
Thus, the possibility of obtaining an earlier break-up by decreasing the shell thickness was 
confirmed, and this could represent the proper approach to the achievement of the desired 
release behavior. 
 
 
Figure 8: release profiles of 600 µm thick enteric capsular devices containing 30% by weight of 
Explotab® CLV; mean t10% (min) in pH 6.8 buffer and relevant CV highlighted in tables. 
 
4. Conclusions 
The use of capsular containers suitable for conveying different types of drug formulations 
and determining the relevant release performance was recently proposed; for the 
manufacturing of such devices, IM technique was exploited because of the advantages it 
would offer in terms of versatility (dimensions, composition and shape or shape details), 
scalability and patentability of the relevant products. In this work, the development of 
enteric soluble capsules based on HPMCAS was approached. The feasibility of the 
manufacturing process with a polymeric formulation containing a plasticizer and a release 
modifier or mixtures of different types of release modifiers (a soluble pore former and a 
disintegrant, i.e. Kollicoat® IR and Explotab® CLV, respectively) was assessed. This basic 
composition showed promising results with respect to a possible fine tuning of the 
thickness and mechanical characteristics of the capsule shell. The formulation-based 
approach undertaken was therefore effective in assessing the main requirements of the 
molded capsular device. Accordingly, the development process would be worth pursuing 
by the design of a dedicated mold and set up of suitable operating conditions while 
finalizing the formulation parameters. 
52 
Acknowledgments 
The support of Consortium TEFARCO Innova and Regione Lombardia, Fondo Sociale 
Europeo is gratefully acknowledged. 
  
53 
References 
1. Dulin W., Oral targeted drug delivery systems: enteric coating, in: Wen H., Park 
K. (Eds.), Oral controlled release formulation design and drug delivery: theory to 
practice, John Wiley & Sons publication, New Jersey, 2010, pp. 205-224. 
2. Davis S.S., The design and evaluation of controlled release systems for the gastro-
intestinal tract, J. Control. Release 2: 27-38, 1985. 
3. Gazzaniga A., Giordano F., Sangalli M.E., Zema L., Oral colon-specific drug 
delivery: design strategies, STP Pharma Pratiques 4: 336-343, 1994. 
4. Gazzaniga A., Maroni A., Sangalli M.E., Zema L., Time-controlled oral delivery 
systems for colon targeting, Expert Opin. Drug Deliv. 3: 583-597, 2006. 
5. McGinity J.W., Felton L.A. (Eds.), Aqueous polymeric coatings for 
pharmaceutical dosage forms, third ed., Informa Healthcare, New York, 2008. 
6. Bianchini R., Resciniti M., Vecchio C., Technological evaluation of aqueous 
enteric coating systems with and without insoluble additives, Drug Dev. Ind. 
Pharm. 17: 1779-1794, 1991. 
7. Felton L.A., Haase M.M., Shah N.H., Zhang G., Infeld M.H., Malick A.W., 
McGinity J.W., Physical and enteric properties of soft gelatin capsules coated with 
Eudragit® L 30 D-55, Int. J. Pharm. 113: 17-24, 1995. 
8. Nastruzzi C., Cortesi R., Esposito E., Genovesi A., Spadoni A., Vecchio C., 
Menegatti E., Influence of formulation and process parameters on pellet 
production by powder layering technique, AAPS Pharm. Sci. Tech. 1: E9, 2000. 
9. Siepmann F., Siepmann J., Walther M., MacRae R., Bodmeier R., Aqueous 
HPMC-AS coatings: effect on formulation and processing parameters on drug 
release and mass transport mechanism, Eur. J. Pharm. Biopharm. 63: 262-269, 
2006. 
10. Cerea M., Zema L., Palugan L., Gazzaniga A., Recent developments in dry 
coating, Pharm. Tech. Eur. 20: 40-44, 2008. 
11. Blubaugh F.C., Zapapas J.R., Sparks M.C., An enteric compression coating. I. In 
vitro studies, J. Am. Pharm. Assoc. 47: 857-862, 1958. 
12. Fukui E., Miyamura N., Kobayashi M., Effect of magnesium stearate or calcium 
stearate as additives on dissolution profiles of diltiazem hydrochloride from press-
coated tablets with hydroxypropylmethylcellulose acetate succinate in the outer 
shell, Int. J. Pharm. 216: 137-146, 2001. 
54 
13. Fukui E., Miyamur, N., Yoneyama T., Kobayashi M., Drug release from and 
mechanical properties of press-coated tablets with hydroxypropylmethylcellulose 
acetate succinate and plasticizers in the outer shell, Int. J. Pharm. 217: 33-43, 
2001. 
14. Lau K.K.S., Gleason K.K., All-dry synthesis and coating of methacrylic acid 
copolymers for controlled release, Macromol. Biosci. 7: 429-434, 2007. 
15. Obara S., Maruyama N., Nishiyama Y., Kokubo H., Dry coating: an innovative 
enteric coating method using a cellulose derivative, Eur. J. Pharm. Biopharm. 47: 
51-59, 1999. 
16. Kablitz C.D., Harder K., Urbanetz N.A., Dry coating in a rotary fluid bed, Eur. J. 
Pharm. Sci. 27: 212-219, 2006. 
17. Cerea M., Foppoli A., Maroni A., Palugan L., Zema L., Sangalli M.E., Dry coating 
of soft gelatine capsules with HPMCAS, Drug Dev. Ind. Pharm. 34: 1196-1200, 
2008. 
18. Liu F., Basit A.W., A paradigm shift in enteric coating: achieving rapid release in 
the proximal small intestine of man, J. Control. Release 147: 242-245, 2010. 
19. McConnell E.L., Fadda H.M., Basit A.W., Gut instincts: explorations in intestinal 
physiology and drug delivery, Int. J. Pharm. 364: 213-226, 2008. 
20. Felton L.A., McGinity J.W., The influence of tablet hardness and tablet 
hydrophobicity on the adhesive properties of an acrylic resin copolymer, Pharm. 
Dev. Technol. 1: 381-389, 1996. 
21. Cole E.T., Scott R.A., Connor A.L., Wilding I.R., Petereit H.-U., Schminke C., 
Beckert T., Cadé D., Enteric coated HPMC capsules designed to achieve intestinal 
targeting, Int. J. Pharm. 231: 83-95, 2002. 
22. Felton L.A., McGinity J.W., Enteric film coating of soft gelatin capsules, Drug 
Deliv. Tech. 3: 48-51, 2003. 
23. Porter S.C., Felton L.A., Techniques to assess film coatings and evaluate film-
coated products, Drug Dev. Ind. Pharm. 36: 128-142, 2010. 
24. Mehuys E., Remon J.-P., Vervaet C., Production of enteric capsules by means of 
hot-melt extrusion, Eur. J. Pharm. Sci. 24: 207-212, 2005. 
25. Zema L., Loreti G., Melocchi A., Maroni A., Gazzaniga A., Injection Molding and 
its application to drug delivery, J. Control. Release 159: 324-331, 2012. 
26. Eith L., Stepto, R.F.T., Tomka I., Wittwer F., The injection-moulded capsule, 
Drug Dev. Ind. Pharm. 12: 2113-2126, 1986. 
55 
27. Vilivalam V.D., Illum L., Iqbal K., Starch capsules: an alternative system for oral 
drug delivery, Pharm. Sci. Technol. Today 3: 64-69, 2000. 
28. Gazzaniga A., Cerea M., Cozzi A., Foppoli A., Tavella G., Zema L., 
Pharmaceutical dosage forms for time-specific drug delivery, EP 2317988, 2011. 
29. Gazzaniga A., Cerea M., Cozzi A., Foppoli A., Maroni A., Zema L., A novel 
injection-molded capsular device for oral pulsatile delivery based on 
swellable/erodible polymers, AAPS Pharm. Sci. Tech. 12: 295-303, 2011. 
30. Gazzaniga A., Foppoli A., Maroni A., Cozzi A., Macchi E., Cerea M., Injection-
molded capsular device for oral pulsatile delivery: an in vivo evaluation. 38th CRS 
annual meeting & exposition July 30-August 3, National Harbor, Maryland, 2011. 
31. Rosato D.V., Rosato D.V., Rosato M.G., Injection Molding Handbook, third ed., 
Kluwer Academic (Ed.), Massachussets, 2000. 
32. Hoyle R., Manufacturing components for a micro litre drug delivery system. Eur. 
Med. Device. Technol. 1, 2010. 
33. Gomes M.E., Ribeiro A.S., Malafaya P.B., Reis R.L., Cunha A.M., A new 
approach based on injection moulding to produce biodegradable starch-based 
polymeric scaffolds: morphology, mechanical and degradation behavior, 
Biomaterials 22: 883-889, 2011. 
34. Zhang Y., Brown K., Siebenaler K., Determan A., Dohmeier D., Hansen K., 
Development of lidocaine-coated microneedle product for rapid, safe, and 
prolonged local analgesic action, Pharm. Res. 29: 170-177, 2012. 
35. Heckele M., Schomburg W.K., Review on micro molding of thermoplastic 
polymers, J. Micromech. Microeng. 14: R1-R14, 2004. 
36. Giboz J., Copponnex T., Mèle P., Microinjection molding of thermoplastic 
polymers: a review, J. Micromech. Microeng. 17: R96-R109, 2007. 
37. Koç M., Özel T. (Eds.), Micro-manufacturing: design and manufacturing of 
micro-products, John Wiley & Sons publication, New Jersey, 2011. 
38. Fischer J.M., Handbook of molded part shrinkage and warpage, William Andrew 
Inc., New York, 2003. 
39. Zhang X., Wang Y., Wang J., Wang Y., Li S., Effect of pore former on the 
properties of casted film prepared from blends of Eudragit® NE 30D and 
Eudragit® L 30 D-55, Chem. Pharm. Bull. 55: 1261-1263, 2007. 
40. Schellekens R.C.A., Stellaard F., Mitrovic D., Stuurman F.E., Kosterink J.G.W., 
Frijlink H.W., Pulsatile drug delivery to ileo-colonic segments by structured 
56 
incorporation of disintegrants in pH-responsive polymer coatings, J. Control. 
Release 132, 91-98, 2008. 
41. Liu F., Lizio R., Meier C., Petereit H.-U., Blakey P., Basit A.W., A novel concept 
in enteric coating: a double-coating system providing rapid drug release in the 
proximal small intestine, J. Control. Release 133: 119-124, 2009. 
42. Liu F., Morenoa P., Basit A.W, A novel double-coating approach for improved 
pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract, Eur. J. 
Pharm. Biopharm. 74: 311-315, 2010. 
43. Zweifel H., Maier R.D., Schiller M., (Eds.) Plastics additives handbook, sixth ed., 
Hanser, Ohio, 2009. 
  
 
 
 
 
- Appendix- 
 
 
 
 
 
The content of this chapter has already been published as: 
Zema L., Loreti G., Melocchi A., Macchi E., Del Curto M.D., Foppoli A., Gazzaniga A., 
Preliminary in vivo evaluation of a gastroresistant capsular device prepared by injection molding, 
Transactions 40th CRS Annual Meeting and Exposition, Honolulu, 21st-24th July 2013.  
58 
PRELIMINARY IN VIVO EVALUATION OF A GASTRORESISTANT CAPSULAR 
DEVICE PREPARED BY INJECTION MOLDING 
 
Abstract 
The in vivo release performance of a gastroresistant capsular device based on HPMCAS and 
prepared by injection molding (IM) was preliminarily evaluated in volunteers with respect 
to conventional enteric coated dosage forms. IM capsule prototypes demonstrated 
promising results in terms of opening time after entering the small intestine. 
 
1. Introduction 
A gastroresistant capsular device prepared by injection molding (IM) was recently proposed 
[1]. The feasibility of the manufacturing process with hydroxypropyl methyl cellulose 
acetate succinate (HPMCAS) as the thermoplastic polymeric component was assessed. By 
improving the basic formulation with a plasticizer and channeling agents (soluble polymers 
and/or disintegrants), promising results were obtained with respect to in vitro performance 
and fine tuning of the thickness as well as mechanical characteristics of the capsule shell. 
In the present work, a preliminary in vivo evaluation of 600 μm thick HPMCAS capsules 
containing 30% (w/w on the plasticized polymer) of Explotab® CLV was carried out. For 
this purpose an assembled gastroresistant system was devised, consisting of an enteric-
coated HPMC capsule filled with both fenazon powder and an acetaminophen-containing 
HPMCAS molded unit (Figure 1). The external capsule would dissolve after gastric 
emptying thus releasing its contents: the appearance of fenazon and acetaminophen in 
biological fluids would indicate the opening of the assembled system and of the HPMCAS 
unit, respectively. 
 
 
Figure 1: assembled gastroresistant system and HPMCAS molded capsule. 
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2. Materials and methods 
2.1. Materials 
HPMCAS (AQUOT-LG®; Shin-Etsu, J); polyethylene glycol (PEG 1500; Clariant 
Masterbatches, I); sodium starch glycolate (Explotab® CLV; JRS, D); metacrylic acid 
copolymer (Eudragit® L 30 D-55; Evonik, D); acetaminophen (Atabay, TR); fenazon 
(ACEF, I); HPMC capsules sizes 000 and 2 (V-Caps®, Capsugel, B). 
 
2.2. Methods 
2.2.1. System preparation 
IM gastroresistant (IMGR) capsules: co-milled blends of HPMCAS and PEG 1500 were mixed 
with Explotab® CLV (55:22:23 ratio) in Turbula (Type T2C, WAB, CH), dried in a 
ventilated oven (40°C, 24 h) and transferred into the IM press (BabyPlast 6/10P, 
Chronoplast, Rambaldi, I). Previously set process conditions were adapted to the use of a 
different mold [1,2]. Each capsule was manually filled with 150 mg of acetaminophen and 
sealed with a HPMCAS alcoholic solution. 
Coated gastroresistant (CGR) capsules: size 2 HPMC capsules, filled with 100 mg of fenazon 
and sealed with HPMC aqueous solution, were coated up to a 10 mg/cm2 coating level 
with Eudragit® L 30 D-55 (LDCS Hi-coater equipped with a 1.3 L capacity perforated pan, 
Freund-Vector corporation, US; inlet temperature: 30 °C, air pressure: 12 psi; pan speed:18 
rpm; rate of spraying 2 g/min). 
Assembled gastroresistant (AGR) systems: size 000 HPMC capsules were filled with one IMGR 
capsule, together with 100 mg of fenazon powder, and dip-coated with an alcoholic 
solution of HPMCAS. 
 
2.2.2. In vitro evaluation 
Systems were tested in apparatus 2 USP35 (Dissolution System 2100B, Distek, US) 
according to the Dissolution test for delayed-release dosage forms (Method B, 100 rpm). 
Fluid samples were withdrawn and assayed spectrophotometrically. Time to 10% release in 
pH 6.8 (t10%) was calculated from the release curves. 
 
2.2.2. In vivo evaluation 
Two different studies were carried out involving 9 healthy volunteers (age 26-61 years, 
weight 53-87 kg). In the 1st study the AGR system was administered to 6 subjects; in the 2nd 
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one an IMGR and a CGR capsule were co-administered to 3 subjects. Systems were 
ingested with 250 mL of water. Saliva samples were collected at predetermined time points 
and immediately frozen; acetaminophen and fenazon were selected because they can be 
assayed in saliva. After defrosting, each sample was centrifuged at 4000 rpm for 15 min. 1 
mL of supernatant was transferred into 10 mL plastic tubes along with 1 mL of Ba(OH)2 
0.3 M and 1 mL of ZnSO4 0.3 M. 100 μL of theophylline monohydrate 0.2 mg/mL were 
added as the internal standard. After mixing by vortex for 30 s, samples were centrifuged at 
4000 rpm for 15 min. Acetaminophen and fenazon were simultaneously assayed by 
gradient RP HPLC (Waters Co., US) using a μBondapack™ Phenyl, 150 x 3.9 mm 125 Å 
column (Waters Co., US) heated at 30 °C. Acetate buffer (pH 5±0.1) and CH3CN were 
employed as the mobile phase at a flow rate of 1 mL/min (t0-7min = 95 : 5; t7-10min = 70 : 30; 
t10-15min = 95 : 5 v:v). Detection: spectrophotometer λ 245 nm. The concentration of 
acetaminophen and fenazon was determined from the tracer to internal standard peak area 
ratio. Data were processed by means of Breeze™ software (Waters Co., US). 
 
3. Results and discussion 
All systems showed the expected in vitro performance (Figure 2): fenazon release from 
CGR capsules and AGR systems occurred few minutes after pH change, whereas a 40-50 
min longer latency was observed for IMGR capsules that could be attributed to the shell 
characteristics, mainly their thickness [1]. 
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Figure 2: in vitro release profiles of AGR, CGR and IMGR systems (top to bottom). 
 
62 
As far as the in vivo studies are concerned, the time of first detection in saliva of 
acetaminophen or fenazon, contained in each administered dosage form, was used to 
define the relevant opening time (see examples in Figure 3 and Figure 4). Based on data 
obtained following administration of the AGR system, a mean opening time of 117 min 
(CV 43.9) after fenazon appearance was calculated for the IMGR capsule, which was 
assumed as the time to disintegration/dissolution of the latter. In the subsequent in vivo 
study, the performance of molded HPMCAS (IMGR) capsules was compared with that of 
conventional enteric-coated ones (CGR). On coadministration of the two systems, 
acetaminophen release from IMGR capsules on average occurred only 35 min after 
fenazon release from CGR ones (Table 1). 
The overall results obtained seem to be in agreement with data reported in the literature 
relevant to gastroresistant dosage forms, generally indicating up to 2 h for their complete 
disintegration/dissolution in the human small intestine [4]. 
 
 
Figure 3: saliva concentration profiles following administration of the AGR system  
(subject #2). 
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Figure 4: saliva concentration profiles following coadministration of CGR and IMGR capsules 
(subject #9). 
 
Table 1: in vivo data of CGR and IMGR capsules. 
opening time, min (CV) 
Δ 
min 
CGR capsules IMGR capsules 
160 (42.3) 195 (35.3) 35 
 
4. Conclusions 
An IM gastroresistant capsular device, suitable for conveying different types of drug 
formulations, was evaluated in vivo, demonstrating the ability to release its contents in the 
intestine. Promising results were obtained in terms of opening time (i.e. an only 35 min 
longer latency as compared with conventional enteric-coated capsules), especially in view of 
the thickness of the prototypes employed. 
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EVALUATION OF HOT MELT EXTRUSION TECHNIQUE IN THE 
PREPARATION OF HPC MATRICES FOR PROLONGED RELEASE 
 
Abstract 
The aim of the work was to explore the potential of hot melt extrusion (HME) for 
preparing hydroxypropyl cellulose (HPC)-based prolonged-release matrices intended for 
oral administration. For this purpose, compressed and extruded systems, either composed 
of polymer only or containing different amounts of a model drug (theophylline or 
ketoprofen), were compared. The overall morphological/physical changes of the systems 
following interaction with water indicated that the manufacturing process would not exert a 
major influence on the swelling behavior of the polymeric matrices. On the other hand, the 
release rate was generally higher from HME systems probably due to an increase of the 
drug dissolution rate, which is in agreement with the relevant DSC data (loss of drug 
cristallinity). However, the technological characteristics of the matrices and the maximum 
drug load were demonstrated to depend on the mode of interaction of the active ingredient 
with the molten polymer. In this respect, the formation of a composite material from 
ketoprofen and HPC, when mixed in specific ratios, was supposed to explain the 
differences observed between compressed and extruded systems in terms of morphological 
characteristics, hydration/swelling and release. The obtained results support the possibility 
of exploiting the advantages offered by HME technique, above all the potential for 
continuous manufacturing, in the preparation of prolonged-release swellable matrices based 
on a cellulose derivative. 
 
Contents 
1. Introduction 
2. Materials and methods 
3. Results and discussion 
4. Conclusions 
Acknowledgments 
References 
 
Keywords: hot melt extrusion, prolonged release, hydrophilic swellable matrices, 
hydroxypropyl cellulose, continuous manufacturing, tableting.  
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1. Introduction 
Hot melt extrusion (HME) is a processing technique widely used to convert plastic raw 
materials into a product of uniform shape and density by heating and forcing them through 
a die, generally employing a rotating screw. Despite some limitations implied by the thermal 
stability of drugs and formulation aids as well as the need for thermoplastic carriers, the 
interest in HME has grown over the last 20-30 years in the pharmaceutical field. This can 
be ascribed to the inherent potential of such a technology for automation and development 
of solvent-free manufacturing processes [1,2]. Moreover, mixing and/or compaction 
problems that can be encountered with powder formulations would be overcome by HME, 
and the bioavailability of poorly soluble active ingredients could be enhanced due to the 
formation of solid phases with increased dissolution rate from molecular dispersions of the 
drug within the molten polymeric carrier. Further advances in the field of HME and 
molding techniques might be expected in the near future due to the consolidation of a 
continuous-manufacturing production model that could bring about significant economic 
benefits [3-6]. In this respect, a molding process was indeed selected for the preparation of 
tablets in the first “drug-manufacturing prototype” built up at the Novartis-MIT 
(Massachusetts Institute of Technology) Center for Continuous Manufacturing, which 
turns raw ingredients into finished drug products through six connected units of 
production [7]. 
Several research groups proposed HME for the preparation of single- and multiple-unit 
drug delivery systems, fast-dissolving or prolonged-release formulations, to be administered 
by the oral route or by the transdermal, transmucosal and transungual ones [8,9]. In the 
field of oral prolonged-release systems, different kinds of polymeric materials, either 
insoluble/inert (such as ethylcellulose or methacrylic acid copolymers) or 
hydrophilic/swellable (mainly polyethylene oxide) were investigated in order to produce 
matrices via HME [10-15]. As far as hydrophilic cellulose derivatives are concerned, which 
are broadly used to prepare tableted oral matrices owing to recognized advantages in terms 
of safety, versatility and low costs, their application was limited by the inherent thermal 
behavior. Indeed, the use of hydroxypropyl methylcellulose (HPMC), which is the most 
widely employed matrix-forming polymer, has proven challenging because of its narrow 
processing window, e.g. the difference between glassy–rubbery transition temperature (Tg) 
and degradation temperature [16]. The hydroxypropyl derivative (HPC), on the other side, 
was demonstrated to possess adequate thermoplastic properties and has extensively been 
used to prepare transdermal and transmucosal extruded systems although, at least so far, it 
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has not been evaluated in the manufacturing of orally-administered matrices by HME 
[17,18]. By the way, HPC is characterized by high plastic deformation during compaction 
but also by high elastic recovery after tableting, which might hinder its use as a 
compression filler [19]. Low molecular weight grades of this polymer were proposed as 
carriers in HME to attain solid dispersions of poorly soluble drugs [20]. Moreover, it has 
recently been proposed for the manufacturing of a pulsatile-delivery platform in the form 
of a capsular device prepared by injection molding [21,22]. 
Based on these premises, the aim of the work was to explore the potential of HPC as a 
thermoplastic carrier for monolithic matrix systems intended for oral prolonged release. In 
this respect, matrices prepared by HME were compared with directly compressed ones. 
The impact of the manufacturing process on the hydration, swelling and erosion rate of the 
polymer was studied by using pure polymeric systems, whereas its feasibility and the 
resulting release performance were evaluated taking drugs with different solubility and/or 
miscibility with the molten carrier into account. 
 
2. Materials and methods 
2.1. Materials 
Hydroxypropylcellulose, HPC: regular and fine (X) grades, 250-300 μm and 80-100 μm 
average particle size, respectively (Klucel® GF and GXF; Ashland, US; Eigenmann & 
Veronelli, I); theophylline (Boehringer Ingelheim, I); ketoprofen (Cosma, I); cellulose 
acetate propionate (CAP 482; Eastman, US). 
 
2.2. Methods 
2.2.1. Powder characterization 
Klucel® GF particle size was evaluated according to Ph. Eur. 7th ed. (7.6) (monograph 
2.9.38 Particle-size distribution estimation by analytical sieving) in the 150-500 μm range; 
Klucel® GXF particle size was evaluated by means of an optical microscope (Axiolab, 
Zeiss, D). Powder d90 and d50 were calculated as reported in monograph 2.9.35 Powder 
fineness. The bulk and tapped density as well as compressibility of the powder were 
determined according to monograph 2.9.34 Bulk density and tapped density of powders, 
Method 1. 
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2.2.2. Matrix preparation 
Pure-polymer and binary drug/polymer matrices with theophylline or ketoprofen content 
in the 5-70% or 5-40% range, respectively, were prepared by direct compression (DC) as 
well as hot melt extrusion (HME) after mixing the powders in Turbula (type T2A-Willy A, 
Bachofen, CH; 10 min). Powder samples of 150 mg were manually filled in a single-punch 
machine (Korsch, EKO, D; flat-faced punch, diameter 8 mm) and tableted at 35 kN. The 
compression force (FA) was measured during the process. HME was carried out in a 
single-screw extruder (Extrusiograph 19/25D, Brabender, D) equipped with a rod-shaped 
die (diameter 8 mm). Process parameters, processing time and torque values recorded while 
manufacturing pure-polymer matrices are reported in Table 1. Extruded products, stored at 
room temperature for 48 h, were cut into matrices with same nominal weight of the 
corresponding DC tablets by means of a bench-top saw. 
 
Table 1: process and output parameters relevant to HME matrices. 
Process parameters Barrel temperature (°C) 150-155-160 
Output parameters 
Die temperature (°C) 150 
Screw speed (rpm) 15 
Processing time (min) 4-6 
Torque range* (N∙m) 7-10 
  * work of the rotating screw needed to convey the material along the heated barrel 
 
All systems were characterized for: weight (Crystal, Gibertini, I), diameter and thickness 
(digital micrometer CD-C112XB, Mitutoyo, J), crushing force (FC) (crushing tester 
TBH28; Erweka, D), surface wettability (contact angle test) and drug content. Cohesion 
index values were also calculated as . 
 
2.2.3. Release test 
Drug release was evaluated by a dissolution Ph. Eur. 7th ed. apparatus 2 (Dissolution System 
2100B, Distek, US) using 900 ml of deionized water at 37 ± 0.5 °C and 50 rpm; throughout 
all tests sink conditions were maintained. Drug concentration in the release medium was 
determined by spectrophotometer (lambda25, Perkin Elmers, UK) at λmax of 272 and 260 
nm for theophylline and ketoprofen, respectively (n = 6, bars in figures indicate standard 
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deviation). Prior to release testing, matrices were manually coated on all surfaces except for 
one base with an impermeable film of CAP (15% w/v acetone solution) [23]. 
 
2.2.4. Interaction with aqueous fluids 
Water uptake and residual dry polymer of matrices immersed in unstirred water at room 
temperature were evaluated over 6 h (n = 3). Systems glued on a glass holder were 
immersed in 100 mL of deionized water, removed after predetermined time periods, gently 
blotted and weighed. In the case of drug-containing matrices, the amount of theophylline 
or ketoprofen released in the medium was spectrophotometrically determined (D rel). Final 
dry weights were also determined after maintaining samples in an oven at 60 °C for 48 h. 
Two parameters were calculated, the % water uptake and the % residual dry polymer, 
according to the following equations: 
 
where Ww is the weight of the wet sample on withdrawal, Wd is the weight of the sample 
after drying; 
 
where Wi is the initial weight of the sample, Drel is the amount of drug released, Dload is the 
nominal drug content. 
The progression of swelling and erosion fronts was determined on coated matrices 
maintained under the same conditions as for the release test. Samples (n = 3) were 
recovered from the immersion fluid at predetermined time points. The position of the 
fronts was determined by means of a 0.01 mm-calibrated penetrometer (Dial Thickness 
Gage 7305, Mitutoyo, J) provided with a 0.3 mm diameter pin. 
 
2.2.5. Thermal analysis 
Powder and extruded samples were characterized by differential scanning calorimetry (DSC 
2010, TA instruments, US) from 30 to 350 °C at 5 °C/min, N2 purge 70 mL/min. 
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2.2.6. SEM analysis 
Photomicrographs of gold-sputtered (10 nm) samples were collected by a scanning electron 
microscope (SEM; Sigma, Zeiss, D). 
 
3. Results and discussion 
3.1. Pure-polymer matrices 
In order to explore the influence of the manufacturing technique on the performance of 
hydrophilic swellable matrices, pure polymeric systems prepared by DC and HME were 
preliminarily considered. A high molecular weight HPC was selected as the matrix-forming 
agent. Particularly, two different commercial types of the polymer were available, a regular 
particle size Klucel® GF (KGF) and a fine one (KGXF). Thus, their flowability and 
compaction tendency were evaluated as they could have impacted on the selected 
manufacturing processes (Table 2). 
 
Table 2: physico-technological properties of HPC type KGF and KGXF (s.d. values in brackets). 
 
d50 
 µm 
d90 
µm 
Bulk density 
 g/mL 
Compressibility index 
 % 
Cohesion index 
 
KGF 290 490 0.39 (0.01) 19 (1) 292 (11) 
KGXF 82 164 0.22 (0.02) 29 (2) 508 (15) 
 
The poor flow characteristics (compressibility index in the 26-31 range; Ph. Eur. 7th ed. 
2.9.36 Powder flow) of KGXF could indeed negatively influence both the tableting 
process, impairing the weight uniformity of the resulting matrices, and the 
continuous/automatic filling of the extruder. With regard to the compaction properties, 
coherent tablets where obtained with both polymer types by the application of relatively 
high compression forces (>25 kN) only. These presented a smooth and gloss surface as 
well as a tendency to deformation instead of breaking when undergoing the crushing test, 
thereby confirming in the case of Klucel® GF the same plastic behavior shown upon 
tableting by other HPC grades with a different molecular weight [19]. In the 
photomicroghaps of DC matrices, two different areas can be distinguished, an external 
packed layer and an internal core exhibiting a pore network (Figure 1a and b). In both 
areas, and especially in the external one, partially molten aggregates of polymer particles 
can be observed, which are particularly evident in the KGXF system (Figure 1b). 
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Moreover, consistent with a presumably wider area exposed, the fine polymer grade 
displayed a higher cohesion index, and the relevant tableted products showed a lower 
porosity. Therefore, DC matrices were finally prepared with KGXF by manually filling the 
tableting machine to overcome the problems connected with the poor flowability of the 
powder, while the coarser material was preferred for the extrusion process. Only with 
KGF, by adjusting the operating parameters, continuous manufacturing of cylindrical 
extrudates based on pure polymer could indeed be performed, with no need for any 
adjuvant. 
 
 
Figure 1: photomicrographs of pure polymer matrices: (a) KGF- and (b) KGXF-based DC 
systems, (c) KGF-based HME systems, at 100x (a1, b1, c1) or 500x (a2, b2, c2) magnification. 
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Pure-polymer matrix systems were characterized in terms of physical properties and 
behavior in aqueous fluids, i.e. water uptake/solvent penetration, swelling, 
dissolution/erosion and wettability. The relevant data are reported in Table 3 and Figure 2. 
 
Table 3: physico-technological properties of pure polymer matrices (s.d. values in brackets). 
 Diameter 
mm 
Thickness 
mm 
Density 
g/cm3 
Crushing force 
N 
Contact angle 
° 
DC 7.99 (0.01) 2.92 (0.06) 0.88 (0.02) 166 (9) 47 (2) 
HME 8.01 (0.06) 2.90 (0.01) 1.05 (0.10) - 49 (3) 
 
 
 
Figure 2: water uptake (■; ▲) and residual dry polymer (□; △) profiles (a), and swelling (■; ▲) and 
erosion (□; △) front profiles (b) of HPC matrices manufactured by DC (dotted lines) and HME 
(solid lines). 
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HME systems showed higher bulk density values, close to the true density of the pure 
polymer (1.15 g/cm3). No particles of the coarse starting polymer could be distinguished in 
the photomicrograph of the extruded product, which also exhibited a lower porosity as 
compared with both the DC systems (Figure 1c). During the crushing strength test, HME 
units got deformed thus hindering the evaluation of the hardness characteristics. 
DC and HME polymeric matrices had very similar wettability. 
In the case of hydrophilic swellable matrices based on HPMC, it is well known that 
differences in the dry polymer particle size may only affect the initial hydration rate and 
thereby impact on the burst release phase, especially with very soluble drugs. Accordingly, 
in spite of the difference in porosity, the HPC matrices prepared by DC and HME showed 
an analogous behavior in contact of interaction with aqueous fluids, as pointed out by very 
similar water uptake, dry mass loss and solvent penetration (swelling) front profiles (Figure 
2). 
 
3.2. Drug-containing matrices 
In order to evaluate the release performance and the influence of drug load, DC and HME 
systems containing increasing amounts of an active ingredient were prepared. Theophylline 
and ketoprofen were chosen as model molecules as they are characterized by melting 
points markedly above or below the HPC extrusion temperature, respectively (271.9 °C for 
theophylline and 95.8 °C for ketoprofen). The ability of ketoprofen to form solid solutions 
with low molecular weight grades of HPC on HME processing was already demonstrated 
as the drug and the polymer were found miscible [24]. Ketoprofen was confirmed to act 
like a plasticizer for KGF, progressively lowering the torque value recorded up to 1-3 N m 
as a function of concentration. On the other hand, a maximum load of 40% could be 
achieved still maintaining an acceptable mechanical resistance of the extrudate. At the 
highest drug load, the operating temperatures needed to be decreased below 100 °C. 
Ketoprofen-containing HME matrices were all transparent with no evidence of dispersed 
particles, as shown by the relevant photomicrographs (Figure 3a). However, while the 
extrudate with the 5% load appeared quite similar to the extruded polymer as such (Figure 
3a1), the aspect of the sample containing 40% of drug was very different, presenting an 
exfoliated surface split into thin flakes (Figure 3a2). 
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Figure 3: photomicrographs of HME matrices containing (a) ketoprofen, 5 (a1) or 40% (a2), and 
(b) theophylline, 5 (b1) or 70% (b2). 
 
With respect to the HME matrices containing the high-melting model drug, products 
loaded up to 70% were obtained with no need for changing the operating conditions set 
for the pure polymer, thus suggesting a lesser ability of theophylline to plasticize the 
polymer. The matrices turned opaque already with 5% of this drug, and the matt 
appearance progressively increased with the loaded amount suggesting that theophylline 
would remain suspended in the polymeric carrier. The presence of solid particles was 
confirmed by SEM analysis (Figure 3b). However, as in the case of ketoprofen, a tendency 
of the torque value to diminish during the extrusion of drug-loaded materials was noticed, 
which could indicate a partial solubilization of theophylline in the molten polymer. In 
thermograms of HME formulations containing decreasing amounts of theophylline, from 
70% to 5%, a progressive reduction of the drug melting peak and shift towards lower 
temperatures was observed, pointing out a gradual loss of crystallinity possibly due to 
drug–polymer interactions (Figure 4) [24]. On the other hand, the drug melting peak was 
evident in none of the thermograms of ketoprofen-based HME formulations. With the 
low-melting model drug, modifications of the area and position of the peak were observed 
when changing the processing technique irrespective of the drug content. By way of 
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example, thermograms relevant to formulations containing 20% of ketoprofen processed 
by mixing, tableting or HME are reported (Figure 5). 
 
 
Figure 4: DSC thermograms of KGF, theophylline and HME matrices containing differing 
amounts of theophylline (5-70%). 
 
  
Figure 5: DSC thermograms of KGF, ketoprofen and formulations containing 20% of drug 
processed by differing techniques. 
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The drug content of HME systems was found >97% of the nominal load for all 
formulations except for those with 60% and 70% of theophylline, for which it turned out 
<95%. This result was attributed to the poor conveying and mixing ability of single-screw 
extruders and might be improved by changing the using equipment (twin-screw extruder). 
As far as the DC products are concerned, they needed to be manufactured manually and 
showed not fully satisfactory mechanical characteristics. In particular, the matrices 
containing theophylline exhibited lower mechanical resistance as compared with pure-
polymer ones, whereas the crushing strength of ketoprofen-containing systems was not 
determinable because deformation occurred. In this respect, it might thus be hypothesized 
that the increase in the micro-environmental temperature brought about by compaction 
could lead to the softening/melting of ketoprofen thereby resulting in plasticization of the 
polymeric matrix. 
Moreover, the polymer compaction was hindered by the presence of both model drugs. 
These findings support the need for identifying alternative manufacturing techniques for 
prolonged-release matrix systems based on HPC. 
Subsequently, the behavior in contact with aqueous fluids (formation and evolution of a gel 
barrier) and the drug release performance of DC and HME matrices were comparatively 
evaluated. The profiles of water uptake, dry polymer loss and swelling as well as erosion 
fronts of systems containing the smallest and the largest amounts of drug are reported in 
Figure 6 and Figure 7. The position of swelling and erosion fronts was not measured for 
extruded products with ketoprofen loads ⩾30% as the relevant glassy portion did not 
withstand penetration of the pin device used for the experiment. 
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Figure 6: water uptake (■; ▲) and residual dry polymer (□; △) profiles of HPC matrices 
manufactured by DC (dotted lines) and HME (solid lines) containing differing percentages of drug. 
 
 
Figure 7: swelling (■; ▲) and erosion (□; △) front profiles of HPC matrices manufactured by DC 
(dotted lines) and HME (solid lines) containing differing percentages of drug. 
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With regard to matrices with a 5% drug load, DC and HME systems showed quite a similar 
behavior, which was in turn not different from that of the pure polymer. On the other 
hand, a faster dry polymer mass loss and a reduced gel thickness (distance between the 
erosion and the swelling front) were noticed in the case of systems with 70% of 
theophylline. These results could be attributed to the formation of a less resistant and/or 
continuous gel barrier due to the relatively small amount of swelling polymer. Notably, the 
impact of polymer erosion turned out more evident for the DC systems. Ketoprofen-based 
HME systems with ⩾30% drug loads showed a very low water uptake as compared with all 
the other formulations and particularly with the corresponding DC matrices (maximum 
water content of 30% after 6 h with 40% drug load HME systems vs almost 70% with DC 
ones). Moreover, no gel barrier was observed on the surface even though the position of 
the solvent penetration front could not be estimated as previously mentioned. Also based 
on the morphological aspect of ketoprofen systems with ⩾30% drug loads (Figure 3a2), the 
formation of a new solid phase, in which the hydrophilic nature of the cellulosic polymer 
was countered by the poor water solubility of the active ingredient, was supposed to take 
place, promoted by the interaction of the softened polymer chains with the molten drug. 
Such a hypothesis, however, needs to be supported by further investigation. 
The release profiles of DC and HME systems containing increasing amounts of the two 
model drugs are reported in Figure 8 and Figure 9, respectively. 
 
Figure 8: release profiles of DC (dotted lines) and HME (solid lines) matrices containing differing 
percentages of theophylline. 
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Figure 9: release profiles of DC (dotted lines) and HME (solid lines) matrices containing differing 
percentages of ketoprofen. 
 
HME matrices for prolonged release are generally described as low-porosity systems able 
to ensure a strict control of drug release. Thus, they are used in subcutaneous, ocular or 
vaginal delivery where especially extended release phases are required (>24 h). 
Nevertheless, the sole comparison found between HME and DC systems refers to inert 
ethylcellulose (EC) oral matrices for which the main factor determining the rate of release 
is indeed porosity [25]. In the case of hydrophilic polymers, it was demonstrated that the 
entanglement of swollen macromolecular chains gives rise to meshes of relatively small size 
and, more importantly, independent of the initial porosity of the glassy matrix [26-28]. In 
this study, the drug release rate was generally higher from HME devices than from DC 
ones of analogous composition, practically independent of the model drug employed and 
the relevant content. Because hydration, swelling and erosion/dissolution processes were 
demonstrated only marginally influenced by the manufacturing technique, this trend was 
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attributed to the dissolution rate of the drugs in the microenvironment within the swollen 
matrix. Following extrusion, in fact, a loss of crystallinity was observed with both drugs, 
which could account for an increase in their dissolution rate and, therefore, in the apparent 
solubility gradient across the gel barrier driving drug release. On the contrary, in the case of 
ketoprofen-based systems containing 30% and 40% of drug, the release profiles of DC and 
HME matrices were superimposable for about 1 h whereas a marked decrease in the 
release rate from HME systems and a reverse order of the release patterns became 
afterwards evident. However, such a difference could once again be ascribed to the drug 
that might have promoted, by melting, the previously discussed increase in hydrophobicity 
of the matrix system and consequent slowing down of solvent-driven processes, i.e. 
hydration/swelling of polymeric chains and dissolution of drug particles. 
 
4. Conclusions 
As HPC was demonstrated critical in terms of compaction properties, the identification of 
an alternative technique for the preparation of oral prolonged-release matrices based on 
such polymer was considered of interest. In particular, because of its thermoplasticity, the 
use of HME, which has recently received attention especially due to its potential for 
continuous manufacturing, was investigated. Promising results were obtained as regards key 
aspect such as process feasibility (e.g. continuous manufacturing with no need for adjuvants, 
working temperatures in the 100-150 °C range, drug loads up to 70%) and technological 
characteristics (e.g. very low porosity, evidence of drug/polymer interaction, increase in the 
microenvironmental apparent solubility of the drug). The impact of the melting 
temperature of the active ingredient on the process conditions and the characteristics of 
the extruded products was highlighted. The overall results indicated that HME would be an 
advantageous technique for the manufacturing of swellable prolonged-release matrices, 
worthy of further investigation and wider application. 
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EVALUATION OF HOT MELT EXTRUSION AND INJECTION MOLDING FOR 
CONTINUOUS MANUFACTURING OF IMMEDIATE RELEASE TABLETS 
 
Abstract 
The exploitation of hot melt extrusion and injection molding for the manufacturing of 
immediate release (IR) tablets was preliminarily investigated in view of their special 
suitability for continuous manufacturing, which represents a current goal of pharmaceutical 
production because of its possible advantages in terms of improved sustainability. 
Tablet-forming agents were initially screened based on processability by single-screw 
extruder and micromolding machine as well as disintegration/dissolution behavior of 
extruded/molded prototypes. Various polymers, such as low-viscosity 
hydroxypropylcellulose, polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol graft 
copolymer, various sodium starch glycolate grades (e.g. Explotab® CLV) that could be 
processed with no need for technological aids, except for a plasticizer, were identified. 
Furthermore, the feasibility of both extruded and molded IR tablets from low-viscosity 
hydroxypropylcellulose or Explotab® CLV was assessed. Explotab® CLV, in particular, 
showed thermoplastic properties and a very good aptitude as a tablet-forming agent, 
starting from which disintegrating tablets were successfully obtained by either techniques. 
Prototypes containing a poorly soluble model drug (furosemide), based on both a simple 
formulation (Explotab® CLV and water/glycerol as plasticizers) and formulations including 
dissolution/disintegration adjuvants (soluble and effervescent excipients) were 
demonstrated able to fulfill the USP 37 dissolution requirements for furosemide tablets. 
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1. Introduction 
Pharmaceutical industry is considered one of the most dedicated to innovation, as the total 
expenditure on research and development over US $ 100 billion could confirm [1]. 
However, only marginal attempts at improving the manufacturing efficiency have been 
reported, even though this has been highlighted as a very promising area of interest, 
especially with respect to the sustainability of dosage form development and manufacturing 
[2]. Traditionally, medicines have ever been manufactured through a batch method, in 
which materials are charged before the start of the process and discharged at the end. The 
final dosage form is obtained stage by stage over a series of workstations. This approach 
has been exploited for decades and it allows all regulatory requirements to be fulfilled. 
However, it does not offer adequate flexibility in responding to demand changes. As a 
consequence, in the last ten years the interest in the potential application of continuous 
manufacturing (CM) to the pharmaceutical field has been growing [3-6]. CM consists in 
producing/processing, without interruption, materials generally maintained in motion and 
undergoing chemical reactions or mechanical/heating treatments. Nowadays, this method 
is largely used in oil refining and production of paper as well as chemicals, where 
continuous commonly means operating 24 hours per day, 7 days per week with infrequent 
maintenance shutdowns, such as semi-annual or annual. According to the Food and Drug 
Administration (FDA), continuous processing has the potential for improving product 
quality and the industry is encouraged to truly consider a shift to it. Moreover, such a 
method was shown consistent with FDA‟s efforts towards quality by design 
implementation. Advantages related to CM are undeniable. It could reduce the time and 
costs of development simply by avoiding the moving of materials among facilities, limiting 
the stored amount of hazardous chemicals thus improving sustainability, overcoming the 
need for stopping, re-configuration and testing between batches as well as that for scaling 
up. In fact, transfer from pilot-plant to full-production scale could be accomplished just 
increasing the process time or making more lines work in parallel. Thanks to the restrained 
dimensions of the equipment required, a further increase of process efficiency could be 
achieved through a better exploitation of the manufacturing area. 
Although many examples of continuous pharmaceutical processes that are run in a batch 
mode (e.g. blending, granulation, drying, tableting) have been reported [7-12], the first end-
to-end (i.e. from drug synthesis to dosage form production) integrated CM plant was only 
very recently proposed [13-15]. Such a plant involves the flow of components trough 
different individual units, where all the conditions/parameters are clearly defined and 
89 
controlled. A prototype tablet intended for immediate release (IR) was achieved by 
extruding a basic thermoplastic formulation of an in situ synthesized model drug, followed 
by its injection into a properly shaped mold. Hot-processing techniques, such as hot melt 
extrusion (HME) and injection molding (IM), would especially be suitable for fulfilling the 
needs of CM. The use of these manufacturing techniques would also result in the 
possibility of carrying out solvent-free processes, overcoming mixing and/or compaction 
issues associated with powder formulations, increasing the bioavailability of poorly soluble 
drugs by the formation of solid dispersions/solutions and the patentability of the obtained 
products as well as the relevant versatility in terms of size and shape [17,18]. HME and IM 
are also mentioned in the pharmacopoeial monograph relevant to tablets (Eur. Pharm. 7th 
ed.). Only a preliminary research paper published in the late „90s, however, has preceded 
the above quoted CM study [16]. So far, polyethylene glycol (PEG) was considered as the 
sole thermoplastic vehicle without any broadening of the formulation study. 
Therefore, the use of hot-processing techniques for the production of IR tablets still needs 
to be explored. In particular, an attentive formulation set-up is required to offset the poor 
porosity that is typical of extruded/molded items and may impair a prompt drug 
dissolution. Because IR tablets represent the top-selling dosage form in the pharmaceutical 
market, their CM would indeed be a remarkable accomplishment and could open the way 
for many other products. Based on these premises, the aim of the present work was the 
evaluation of polymeric components and the identification of formulations strategies for 
the achievement, by HME and IM, of solid units having acceptable IR characteristics (high 
disintegration/dissolution rate), thus strengthening the use of these innovative techniques 
and ultimately supporting progress in CM within the pharmaceutical field. 
 
2. Materials and methods 
2.1. Materials 
Hydroxypropyl cellulose (HPC; Nisso SSL, Nisso, J); hydroxypropyl methyl cellulose 
(HPMC; Methocel® E5, Colorcon, US); polyvinyl alcohol (PVA; Gohsenol®, Nippon 
Goshei, UK); polyvinyl alcohol-polyethylene glycol graft copolymer (KIR; Kollicoat® IR, 
BASF, D); polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer 
(Soluplus®; BASF, D); metacrylic acid copolymer (Eudragit® E PO; Evonik, D); corn starch 
(Ingredion, Westchester, US); sodium starch glycolates (EXP, Explotab®; EXPCLV, 
Explotab® CLV; VIV, Vivastar®; JRS Pharma, D); vinylpyrrolidone-vinyl acetate copolymer 
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(KVA; Kollidon® VA 64, BASF, D); deionized water (W); glycerol (GLY; Pharmagel, I), 
polyethylene glycols (PEG; 400, 1500, 6000 and 8000, Clariant Masterbatches, I); talc 
(Carlo Erba, I); croscaramellose sodium (AcdiSol®; FMC BioPolymer, US); low-substituted 
hydroxypropyl cellulose (L-HPC; ShinEtsu, J); sodium chloride (NaCl; Carlo Erba, I); 
sodium hydrogen carbonate (NaHCO3; Carlo Erba, I); calcium carbonate (CaCO3; Carlo 
Erba, I); citric acid (Carlo Erba, I); tartaric acid (Carlo Erba, I); furosemide 
(Metapharmaceutical, E). 
 
2.2. Methods 
2.2.1 Characterization of materials 
Hot-plate experiment: 2-3 g samples of polymer/polymeric formulation were placed in an 
aluminum pan on a hot plate and heated under continuous manual mixing, while gradually 
increasing the temperature up to 200 °C. Samples were checked for overall aspect, color, 
texture and mechanical characteristics during heating and after cooling. 
Air shot test: 50 g samples of polymer/polymeric formulation were loaded into the IM press 
through the hopper and expelled from the injecting unit as during a purge operation [19]. 
The test was repeated under different operating temperatures. Samples were checked for 
overall aspect, color and mechanical characteristics immediately after ejection and after 
cooling. 
X-Ray diffraction: X-ray diffractograms were collected with a X'pert Pro MPD diffractometer 
(Panalytical, US), using Cu-Kα radiation (λ=1.5418 Å). The generator voltage and current 
were set at 45 kV and 40 mA, respectively and the 2 - theta scanning range was from 4 to 
40° (step size 0.0083556°, scan speed 0.053907 °/s). Powder samples and 
extruded/molded samples of uniform thickness were analyzed. 
 
2.2.2 Manufacturing of extruded and molded units 
Tablet-forming polymers, except for PEGs, were kept in a ventilated oven at 40 °C for 24 
h prior to use. Plasticized polymeric formulations were prepared by mixing or granulating 
polymers in a mortar with the selected solid or liquid plasticizer, respectively; the amount 
of plasticizer was expressed as weight % (wt%) on the dry polymer. Adjuvants and/or drug 
were added to plasticized formulations by mixing in a mortar; the amount of the added 
component was expressed as wt% on the final formulation. As far as starch and starch 
derivatives are concerned, final formulations to be processed by IM were prepared by 
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extrusion through a 4 mm rod-shaped die (see HME process). Only for the EXPCLV-based 
formulations containing effervescent adjuvants, the latter were added after extrusion, in 
order to limit their early contact with water and exposure to high temperatures. 
HME process: HME was carried out by a single-screw extruder (Extrusiograph 19/25D, 
Brabender, D) equipped with rod-shaped (diameter 4 or 8 mm) or ribbon-shaped 
(thickness 1 mm) dies. Process parameters (barrel T1-T2-T3 and die T4 temperatures, screw 
rate) and torque values were recorded. Rods of 4 mm in diameter were manually cut into 
pellets and then processed by IM; rods of 8 mm in diameter rods were cut into tablets 
(thickness 4 mm) by a bench-top saw. Rods of 30 mm in diameter disks were die-cut from 
extruded sheets.  
IM process: IM was performed by a bench-top micromolding machine (BabyPlast 6/10P, 
Cronoplast S.L.; Rambaldi S.r.l., I). Materials were loaded through the hopper into the 
plasticating chamber of the IM press by means of the loading plunger and then conveyed 
to the injecting chamber. By successively applying two distinct pressures, the injection 
pressure P1 (maintained for 2.5 sec) and the holding pressure P2 (maintained for 1.5 sec), 
both at a selected rate (r1 and r2, respectively) expressed as a percentage of the maximum 
one, a second plasticating plunger (10 mm diameter) moved 7-16 mm forward thus 
injecting specific amounts of formulation through a 1 mm nozzle into the mold cavity. 
Molded items were prepared by way of two different molds: i) a disk-shaped mold of 30 
mm in diameter and 1 mm in thickness provided with a central gate; ii) a cylindrical mold 
of 8 mm in diameter and 4 mm in height provided with a central gate. Prior to product 
ejection, the mold was kept closed (2.5-15 sec at 15 °C) and the formulation was allowed to 
cool down and harden. The disk-shaped mold was manually lubricated with vegetable oil 
approximately every 20 manufactured units; the first disk obtained after this operation was 
discarded. 
 
2.2.3 Characterization of extruded and molded units 
HME and IM units were checked for weight (analytical balance BP211, Sartorius, US; n = 
10) and thickness (digimatic indicator ID-C112X, Mitutoyo, J; n = 10). 
Digital photographs (Nikon D70, Nikon, I) and photomicrographs (SEM; Sigma, Zeiss, D; 
gold sputtering, 10 nm) of tablets not exposed to the aqueous medium and withdrawn at 
different time points during the mass loss test were acquired; samples dried in a ventilated 
oven at 40 °C for 24 h were evaluated. 
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Mass loss test: the mass loss test on extruded and molded placebo units (disks and tablets) (n 
= 3) was carried out in both a USP37 dissolution apparatus (apparatus 2, Dissolution System 
Distek Inc. 2000, US; 1000 mL of distilled water or 1N HCl solution, 37 ± 0.5 °C, 100 
rpm) and in a six-position disintegration apparatus (800 mL of distilled water or HCl 1N, 37 
± 0.5 °C, 31 cycles/min). Samples to be tested by dissolution apparatus were inserted into 
a polyethylene net (5 mm mesh for disks and 2 mm mesh for tablets). Tablets to be tested 
by disintegration apparatus were inserted each into a single basket-rack assembly. At pre-
determined time points samples were withdrawn and oven-dried (40 °C) to constant 
weight. Percentage mass loss was calculated with respect to the initial sample weight. Times 
to 10 and 80 % mass loss (t10 and t80, respectively) were obtained from mass loss data and 
the difference between the two values (t80-10) indicated mass loss rate. 
Dissolution test: the drug dissolution test (n = 3) was performed by USP37 apparatus 2 
(Dissolution System Distek Inc. 2000, US) under the following operating conditions: 900 
mL of pH 5.8 phosphate buffer, 37 ± 0.5 °C, 50 rpm, according to “Furosemide Tablets” 
USP37 monograph. Fluid samples were withdrawn at fixed time points and assayed 
spectrophotometrically (274 nm). At the end of the test (90 min), the total amount of drug 
dissolved was determined after vortex mixing (10 min). The percentage of furosemide 
dissolved at each time point was calculated with respect to the final dissolved amount. 
Dissolution parameters were statistically compared by umpired 2-tail t-student test, 
accounting for heteroscedasticity. The differences were considering significant with p < 
0.05. 
 
3. Results and discussion 
HME and IM are well established processing techniques in the plastics industry. Despite 
the number of applications proposed in the scientific literature, there is still much work to 
be done before they may widely be exploited in the pharmaceutical industry, especially in 
the case of IM. Not only problems related to the processability of pharma-grade materials 
(rheological/thermomechanical behavior and stability), but also limitations associated with 
the active ingredient (dose, physical-chemical characteristics and stability) and the drug 
product requirements (release profile, physical characteristics and stability, route of 
administration, compliance) should be taken into account. In this respect, as no 
formulation approaches have been described for the manufacturing of IR tablets by HME 
or IM, the first objective of the present work was the identification of pharma-grade 
93 
polymers suitable for being processed and able to lead to products having the desired 
performance. Such polymers should not be considered merely as conventional fillers 
because they represent the thermoplastic components essential to the achievement of the 
final dosage form, i.e. the tablet-forming agents. The dissolution of the active ingredient 
should start as soon as IR formulations come in contact with biological fluids, and the 
dissolution rate should primarily depend on the physical-chemical properties of the drug 
while not being limited by the dosage form characteristics (Eur. Ph. 8th ed., Dosage Forms, 
Glossary). In this respect, HME and IM products, which generally show higher bulk 
density and lower porosity with respect to compressed ones of analogous composition (e.g. 
prolonged-release matrix systems, implants), may turn out critical [12,20,21]. A screening of 
traditional fillers, either soluble or insoluble, known for their thermoplastic properties and 
already proposed for hot-processing, was therefore undertaken. 
 
3.1. Screening of tablet-forming agents 
The possibility of using polymers as tablet-forming agents in HME and IM would depend 
on the processing temperatures and the rheological properties of the melt as well as the 
thermal/mechanical stability of the obtained products that has a great impact on the 
versatility of tablets in terms of shape, dimensions and drug loads. In this respect, based on 
the need for the material to be extruded/injected through thin gaps, which involves higher 
shear stresses, sheets and disk prototypes were employed in order to discriminate the 
behavior of different polymers. 
Soluble polymers used as carriers for solid dispersions prepared by HME (HPC, HPMC, 
PVA, KIR, KVA, Soluplus, Eudragit E) and thermoplastic starch were initially considered 
[22-32]. Also polyethylene glycols (PEG 6000 and 8000), which were the only polymers 
already proposed for the manufacturing of tablets by IM, were taken into account for 
comparison purposes [16]. In addition, the ability of starch derivatives employed as 
disintegrants for solid dosage forms (EXP, EXPCLV, VIV) to behave like thermoplastic 
starch does when processed in the same way, i.e. in admixture with plasticizers, under 
thermal and mechanical stresses, and to maintain hydration/swelling properties, was 
investigated. 
As a preliminary step, hot-plate and air shot tests were performed to determine or confirm 
the working temperatures of the selected polymers and assess whether plasticizers were 
needed or not [33-34]. The choice of the type and amount of plasticizer as well as the 
identification of parameters to be used for the evaluation of HME and IM processability, 
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were then accomplished through the preparation of extruded sheets (1 mm in thickness) 
and molded disk-shaped prototypes (1 mm in thickness and 30 mm in diameter), 
respectively (Table 1). The HME processability of materials under investigation was 
evaluated based on morphological (uniformity of shape and thickness) and mechanical 
characteristics of extruded sheets. On the other hand, IM processability was rated 
according to the aspect (integrity and thickness) and mechanical characteristics of the 
molded disks as well as the possibility of their automatic ejection at the end of a molding 
cycle, thus providing a continuous manufacturing process. 
 Table 1: polymeric formulation and operating parameters used for the manufacturing of extruded sheets and molded disks. 
Formulation Process conditions and performance 
Polymer 
Plasticizer 
(wt %) 
HME IM 
T1-T2-T3 -T4 
°C 
Screw rate 
rpm 
Torque* 
N m 
Processabilitya 
T1-T2-T3  
°C 
P1 
bar 
r1 
% 
P2 
bar 
r2 
% 
Processabilityb 
PEG 6000 - 65-60-60-55 50 1 - 65-60-55 15 20 10 15 - 
PEG 8000 - 65-65-60-55 50 1 - 65-60-55 15 20 10 15 - 
HPC 
PEG 1500  
(10%) 
95-100-110-115 15 9 + 110-115-125 40 30 30 20 + 
HPMC 
PEG 400  
(50%) 
nd nd nd nd 130-140-150 30 50 20 40 -/+ 
KVA 
PEG 1500  
(10%) 
140-150-155-145  30 5 -/+ 140-145-150 30 20 20 15 - 
KIR 
GLY  
(15%) 
150-140-150-140 25 10 + 130-135-150 50 40 30 20 + 
PVA 
GLY  
(20%) 
140-150-160-150 20 7 + 160-170-180 40 40 30 30 + 
Soluplus 
PEG 1500  
(15%) 
90-95-100-120 40 5 -/+ 130-140-150 40 30 30 20 -/+ 
Eudragit E 
TEC  
(10%) 
145-155-160-150 60 10 -/+ 150-155-160 50 40 40 30 -/+ 
Starch 
W (15%) /  
GLY (10%) 
75-90-110-95 55 7 -/+ 125-110-125 40 50 30 40 -/+ 
EXP 
W (20%) /  
GLY (20%) 
60-70-100-90 85 8 -/+ 90-125-120 30 50 20 45 -/+ 
EXPCLV 60-70-100-90 85 9 -/+ 90-125-130 30 50 20 45 -/+ 
VIV 60-70-100-90 85 10 -/+ 90-125-130 30 50 20 45 -/+ 
    *maximum value obtained 
    aHME processability: “-” no sheet obtained; “-/+” incomplete sheet with non-uniform thickness/extreme brittleness; “+” complete sheet with uniform       
      thickness and suitable mechanical properties 
    bIM processability: “-” broken/deformed disks; “-/+”not-automatically disks ejected/ extremely brittle; “+”automatically ejected disks with suitable  
     mechanical properties 
    “nd” not determined; the extrusion process failed  
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A series of promising tablet-forming agents was identified that could be processed by HME 
and IM with no need for technological aids, except for plasticizers that both decreased the 
working temperatures and counteracted the glassy nature of the extruded/molded products. 
In this respect, hot-processing techniques would involve a remarkably limited number of 
excipients as compared with traditional tablet manufacturing by compression. PEGs only 
could be processed as such. However, they were characterized by very low melting points and 
viscosities at their working temperatures, which impaired the achievement of extruded sheets 
or any other item with own consistency. By IM, PEG products could be obtained because this 
technique envisages cooling and hardening inside a mold, nevertheless their original shape was 
not maintained over time. Some difficulties were also encountered in processing HPMC and 
Eudragit E by HME as well as KVA by both the techniques, although these may be overcame 
when changing equipment and/or shape/size characteristics of items produced. 
As far as the starch derivatives are concerned, they demonstrated to become extrudable under 
thermal and mechanical stresses in the presence of water/glycerol mixtures, as already 
observed with starch. However, the amount of plasticizer and the rate of extrusion needed to 
be increased in order to process the starch derivatives. The relevant extruded products showed 
a marked and durable loss of crystallinity. By way of example, X-ray profiles of EXPCLV-based 
samples immediately after extrusion and following six-months storage at ambient conditions 
(24 ± 2 °C, 55 ± 5% RH) are reported in Figure 1. It can be noticed that retrogradation or 
post-crystallization phenomena, typical of thermoplastic starch, did not occur in the case of 
sodium starch glycolate, at least within the considered period of storage [24]. 
 
 
Figure 1: X-ray profiles of powdered Explotab® CLV and polymer-based sheets immediately after 
extrusion and after 6 months storage. 
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Disk-shaped prototypes, obtained by cutting the extruded sheets or by molding, were used to 
study the behavior of the polymeric formulations when in contact with aqueous fluids. 
Parameters calculated from their mass loss profiles are reported in Table 2. 
 
Table 2: mass loss parameters (CV <5%), t10diss (time to 10% of mass loss in the dissolution apparatus) 
and t80-10diss (difference between the time to 80 and 10% of mass loss in the dissolution apparatus), 
relevant to disk-shaped prototypes. 
Formulation HME disks IM disks 
Polymer Plasticizer  
(wt%) 
t10diss  
min 
t80-10diss 
min 
t10diss  
min 
t80-10diss 
min 
PEG 6000 - / / / / 
PEG 8000 - / / / / 
HPC PEG 1500 (10%) < 5‟ 39‟ 24” < 5‟ 21‟ 03” 
HPMC PEG 400 (50%) - - < 5‟ 33‟ 47” 
KVA PEG 1500 (10%) nd nd / / 
KIR GLY (15%) < 5‟ 26‟ 32” < 5 28‟ 44” 
PVA GLY (20%) 10‟ 02” > 60 < 5  40‟ 35” 
Soluplus PEG 1500 (15%) 7‟ 14” 46‟ 50” 8‟ 14” > 60‟ 
Eudragit E TEC (10%) nd nd < 5 * 26‟ 44” * 
Starch 
W (15%) /  
GLY (10%) 
39‟ 20” > 80 10‟ 07” > 90‟ 
EXP 
W (20%) /  
GLY (20%) 
< 5‟ 41‟ 43” < 5‟ 48‟ 59” 
EXPCLV < 5‟ 48‟ 49” < 5‟ 39‟ 55” 
VIV < 5‟ > 60‟ < 5‟ 34‟ 28” 
 “/” neither extruded sheets nor complete disks obtained 
 “nd” not determined; no intact disks could be obtained by cutting 
 * mass loss test was performed in 1N HCl solution 
 
Most of the samples lost at least 10% of the initial mass (t10diss) in less than 10 min, in most 
cases within 5 min, and a further 70% (t80-10diss) within about 60 min. Mass loss could be 
attributed to dissolution phenomena, predominant, as expected, in the case of samples based 
on soluble polymers, and mechanical erosion. The detachment of macroscopic fragments 
from the external surface of disks was evident with starch-derived disintegrants only. 
Differences between the mass loss performance of HME and IM disks with the same 
composition were not observed in spite of possibly different porosities. When present, such 
differences may fail to be highlighted owing to non-properly discriminating test conditions. 
Indeed, because disks were inserted into a polyethylene net, the access of water might be 
restricted and hydration/swelling phenomena, generally leading to the disintegration of solids, 
might consequently be limited. Moreover, fragments larger than the mesh size (> 5 mm) were 
not able to escape through the net, thus not being accounted as mass loss. Such issues were 
overcome when dealing with tablet products. 
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3.2. Placebo tablets 
Two of the polymeric formulations that showed a good balance between HME/IM 
processability and fast mass loss performance, but a different dissolution/disintegration 
behavior, were selected for the manufacturing of tablets. HME and IM processes for the 
preparation of extrudates of 8 mm in diameter, subsequently cut into cylindrical items of 4 
mm in thickness (i.e. final HME tablets), and molded tablets of the same size, respectively, 
based on HPC and EXPCLV were set up (formulations 1a and 2a in Table 3). The 
manufacturing of placebo tablets, i.e. based on thermoplastic tablet-forming agents only, 
turned out to be less critical with respect to that of disks. In particular, IM tablets were 
obtained with no need for lubrication. 
In order to better discriminate between the performance of differently prepared tablets, the 
mass loss test was carried out by both dissolution apparatus, with tablets inserted into a 
polyethylene net of 2 mm mesh, and disintegration apparatus, with tablets freely moving in the 
basket-rack assembly (Figure 2). 
 
 Table 3: composition and operative parameters used for the manufacturing of extruded and molded tablets based on EXPCLV and HPC. 
 
Formulation 
Process conditions 
HME IM 
Polymer Plasticizer 
(wt%) 
Drug 
(wt%) 
Adjuvant 
(30%) 
T1-T2-T3 -T4 
°C 
Screw rate 
rpm 
Torque* 
N m 
T1-T2-T3 
°C 
P1 
bar 
r1 
% 
P2 
bar 
r2 
% 
1a 
HPC 
PEG 1500  
(10%) 
- 
- 95-100-110-115 15 9 120-130-140 30 20 40 30 
1b AcdiSol 100-105-115-110 15 10 130-140-150 30 30 20 20 
1c L-HPC 100-105-115-110 15 10 130-145-150 30 30 20 20 
1d NaHCO3 100-105-115-115 15 12 130-135-130 40 35 30 25 
1e 
NaHCO3 / citric acid / 
CaCO3 
nd nd nd 130-135-130 50 40 40 30 
1f NaHCO3 / tartaric acid nd nd nd 130-135-130 40 40 30 30 
1g NaCl 95-100-110-115 15 18 130-135-130 40 40 30 30 
1h KIR 95-100-110-115 15 24 130-135-140 40 40 30 30 
1i 
Furosemide 
(20%) 
- 90-100-115-115 60 14 100-120-130 30 50 20 40 
1l AcdiSol 90-100-115-115 60 19 100-120-130 30 40 20 30 
1m NaHCO3 / tartaric acid nd nd nd 130-135-130 40 40 30 30 
1n KIR 90-100-115-115 60 12 120-130-140 40 40 30 30 
1o NaCl 90-100-110-115 10 20 120-130-140 45 40 35 30 
2a 
EXPCLV 
W (20%) /  
GLY (20%) 
- 
- 60-70-100-90 65 9 100-130-140 50 20 40 30 
2b AcdiSol 60-70-110-90 40 20 90-130-120 40 40 30 30 
2c L-HPC 60-70-100-90 40 12 120-145-140 50 20 40 35 
2d NaHCO3 60-80-100-90 40 11 110-120-130 40 30 30 20 
2e 
NaHCO3 / citric acid 
CaCO3 
nd nd nd 110-120-130 40 40 30 30 
2f NaHCO3 / tartaric acid 60-80-100-90 40 12 110-120-130 40 40 30 30 
2g NaCl 60-80-100-90 40 8 110-120-130 40 40 30 30 
2h KIR 60-90-110-90 40 8 110-120-130 40 40 30 30 
2i 
Furosemide 
(20%) 
- 60-65-85-80 50 10 100-110-115 30 30 20 20 
2l AcdiSol 80-90-100-95 30 30 100-110-115 30 30 20 20 
2m NaHCO3 / tartaric acid 80-90-100-95 30 25 100-110-115 40 40 30 30 
2n KIR 60-80-100-80 40 12 120-115-120 40 40 30 30 
2o NaCl 60-80-100-80 40 14 110-115-120 50 40 40 30 
     * maximum value obtained 
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Figure 2: mass loss profiles of the HPC- and EXPCLV-based tablets performed in the dissolution (a) or 
disintegration (b) equipment. 
 
The mass loss rate of HME tablets turned out to be higher with respect to IM ones, 
irrespective of composition and test conditions. This could be due to possibly different 
surface and density characteristics of the products. Upon injection under high pressure into 
the mold cavity, in fact, a tight packing of polymer chains and a sudden cooling at the mold 
surface would take place, which may overall account for poor solvent penetration into the 
final item [21,35]. When tested by disintegration apparatus, all tablets except for the molded 
ones based on HPC showed an increase in mass loss over time. The mass loss increase was 
more evident with those materials which are known to possess an intrinsic ability to promote 
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disintegration (EXPCLV vs HPC) or when tablet density could be assumed to be lower 
(extruded vs molded tablets). The different behavior of EXPCLV and HPC formulations when 
exposed to the aqueous fluid was confirmed by the aspect of the tablets recovered. By way of 
example, in Figure 3 photographs of the molded tablets and photomicrographs of their 
surface, before and after exposure to the aqueous medium for different periods of time, are 
reported. 
In the SEM images relevant to EXPCLV-based tablets, cracks can be seen, already after 5 min 
of exposure to aqueous fluids, which could be attributed to the detachment of fragments. On 
the contrary, the surface of HPC tablets appears unchanged. Such findings are consistent with 
hypothesized mass loss mechanisms based on mechanical erosion or dissolution. This was 
confirmed by photographs of samples at successive time points (10-60 min in the dissolution 
apparatus), which pointed out a progressive reduction in volume of the HPC tablets without 
any notable change in their shape, thus supporting the occurrence of dissolution phenomena. 
On the other hand, it was evident that EXPCLV tablets underwent a process of deaggregation. 
 
 
Figure 3: digital photographs and photomicrographs of molded placebo tablets based on HPC and 
EXPCLV, before and after exposure to the aqueous medium. Digital photographs are referred to units 
tested in the dissolution apparatus. 
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3.3. Drug containing tablets 
In order to further evaluate the potential for immediate release of the thermoplastic tablet-
forming agents, a model drug, challenging in terms of dissolution properties, was selected. 
Tablets containing 20% of furosemide [36] (class IV of the Biopharmaceutics Classification 
System; Tm = 206 °C) were prepared by both HME and IM. Process conditions and 
dissolution profiles are reported in Table 3 (formulations 1l and 2l) and Figure 4, respectively. 
 
 
Figure 4: dissolution profiles of HPC- and EXPCLV-based tablets containing furosemide. 
 
Dissolution results from furosemide-containing tablets were in agreement with mass loss from 
placebo ones. In fact, drug dissolution rate turned out higher in the case of extruded tablets 
and EXPCLV-based formulations as compared with molded and HPC-based ones, respectively. 
The HPC-based formulations gave rise to non-disintegrating matrices from which drug 
liberation would occur through the swollen polymer. On the contrary, thermoplastic EXPCLV 
was confirmed to be a very promising filler that would enable the manufacturing of 
disintegrating tablets by the investigated hot-processing techniques. Indeed, extruded 
prototypes having the simplest formulation (i.e. polymer/plasticizer/drug) fulfilled the 
requirements of USP 37 for IR furosemide tablets (i.e. not less than 80 % of furosemide 
dissolved in 60 min). 
103 
The use of dissolution/disintegration adjuvants was also attempted in order to enhance the 
rate of drug liberation. The possibility of adding soluble (NaCl, KIR), effervescent (NaHCO3, 
CaCO3, citric and tartaric acids) and disintegrant (AcdiSol, L-HPC) excipients to HPC and 
EXPCLV formulations was investigated [21,34,37-39]. 
All tablets, either placebo or containing the drug, were successfully prepared after minimal 
adjustments of process parameters (Table 3). Only few HME manufacturing processes 
relevant to placebo formulations containing citric acid or tartaric acid and CaCO3, in 
admixture with NaHCO3 (formulations 1e, 1f, 1m and 2e), failed because of too high shear 
forces to deal with. When tablets containing effervescent excipients were successfully 
prepared, an internal porous structure was observed, especially in the case of HPC-based 
molded samples (Figure 5). This could be attributed to the evolution of CO2 gas resulting 
from the thermal decomposition of sodium bicarbonate in the softened polymer [38]. 
 
 
Figure 5: Photomicrographs of (a) HPC- and (b) EXPCLV-based placebo molded tablets containing 
30% of NaHCO3 / tartaric acid. 
 
Dissolution parameters, i.e. the percentages of furosemide dissolved after 20 and 60 min 
(%20min and %60min, respectively), relevant to adjuvant-containing tablets and reference products 
based on HPC and EXPCLV only are reported in Table 4. 
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Table 4: percentage of furosemide dissolved after 20 and 60 min (%20min and %60min, respectively) from 
HPC- and EXPCLV-based tablets containing dissolution/disintegration adjuvants. 
 Formulation HME IM 
Polymer 
Plasticizer 
(wt%)  
Drug 
(20%) 
Adjuvant 
(30%) 
%20min 
(cv) 
%60min 
(cv) 
%20min 
(cv) 
%60min 
(cv) 
1a 
HPC 
PEG 1500 
(10%) 
Furosemide 
- 
7.02 
(11.05) 
28.93 
(6.42) 
1.47 
(3.15) 
4.47 
(6.44) 
1b AcdiSol 
6.56 
(9.10) 
24.25 
(10.46) 
6.13 
(9.1) 
18.37 
(1.41) 
1e 
NaHCO3 / 
tartaric acid 
- - 
12.95 
(7.92) 
39.13 
(3.05) 
1f KIR 
10.04 
(7.04) 
34.65 
(4.29) 
2.88 
(0.33) 
22.03 
(12.86) 
2a 
EXPCLV 
W (20%) / 
GLY (20%) 
Furosemide 
- 
32.45 
(1.10) 
86.76 
(2.96) 
23.09 
(9.70) 
65.64 
(2.40) 
2b AcdiSol 
6.97 
(14.36) 
28.22 
(22.62) 
5.84 
(9.44) 
17.26 
(6.23) 
2e 
NaHCO3 / 
tartaric acid 
27.93 
(0.86) 
74.93 
(0.46) 
51.58 
(11.25) 
99.8 
(4.57) 
2f KIR 
45.97 
(7.32) 
100.00 
(3.00) 
38.77 
(9.65) 
100.00 
(7.90) 
 
Adjuvants that were demonstrated able to increase the mass loss of HPC tablets (data not 
shown) generally improved the furosemide liberation, mainly from IM products. In particular, 
the best performance was obtained with the molded tablets containing NaHCO3 and tartaric 
acid (> eight-fold amount of furosemide dissolved after 60 min as compared with 1a reference 
formulation). Indeed, these tablets not only showed a porous network but also a residual 
effervescent activity when in contact with the aqueous fluids, which could account for 
improved dissolution. A different behavior was observed in the case of formulations 
containing disintegrants. While mass loss of placebo products was increased by the latter 
adjuvants, AcdiSol slightly improved the dissolution rate of furosemide from molded tablets 
only. Moreover, the disintegrant did not significantly affect (p > 0.05) drug dissolution 
parameters of HME units. 
EXPCLV was confirmed an advantageous filler for the preparation of IR tablets by HME and 
IM. Indeed, three relevant formulations, one of which obtained by HME and the other two by 
IM, fulfilled USP requirements for furosemide tablets. In particular, when taking into account 
the contribution of the adjuvants to the improvement of disintegration and dissolution rate, 
effervescent excipients turned out more effective in molded rather than extruded tablets. 
During IM processing, wherein exposure to high temperatures lasts shorter, thermal 
decomposition of sodium bicarbonate and resulting CO2 evolution would less likely occur. 
Accordingly, a residual effervescence ability might have been maintained thus aiding the 
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disintegration of tablets in contact with aqueous fluids. The addition of the soluble adjuvant 
KIR resulted in enhanced drug dissolution rate, and this effect was comparable or, even better 
in the case of HME tablets, with that of effervescent-containing products. Unlike all other 
EXPCLV-based tablets, neither placebo nor drug-loaded KIR-containing ones gave rise to 
visible residues after the relevant exposure to aqueous fluids. Such a behavior was considered 
worth being further investigated. Finally, in the presence of AcdiSol, the rate of furosemide 
dissolution from both extruded and molded EXPCLV-based products was decreased. The 
ability of the disintegrant to promote mass loss of placebo units in aqueous medium was thus 
not reflected in an enhanced drug dissolution rate. This already occurred with HME HPC-
based tablets containing the same adjuvant. In this respect, the presence of salts in the buffer 
medium might account for a lower amount of water available for the hydration/swelling of 
EXPCLV and/or AcdiSol. Indeed, the dissolution rate of furosemide increased when the test 
was performed under the mass loss experimental conditions, i.e. water instead of phosphate 
buffer as the medium, and 100 instead of 50 rpm: %20min 21.32 (CV 1.89) and %60min 69.16 (CV 
3.36) for HME EXPCLV-based tablets; %20min 40.20 (CV 3.81) and %60min 92.63 (CV 1.21) for 
IM EXPCLV-based tablets. 
 
4. Conclusions 
The possibility of manufacturing tablets with potential for IR by HME and IM techniques, 
which could advantageously fulfill the needs of CM, may help progress of this emerging 
production mode in the pharmaceutical industry. Accordingly, a broad screening of 
pharmaceutical grade polymers was carried out aimed at evaluating the relevant suitability as 
tablet forming agents. Their selection was based on the polymer processability by both 
techniques and the disintegration/dissolution aptitude of the extruded/molded items 
obtained. The dissolution performance of extruded and molded tablets containing the poorly-
soluble drug furosemide as a challenging tracer molecule was also investigated. 
A variety of suitable tablet-forming agents, soluble and insoluble, able to give rise to consistent 
IR tablets starting from simple formulations, in some cases based on the polymer and 
plasticizer only, and showed appropriate behavior in aqueous media were identified. Sodium 
starch glycolate (i.e. Explotab®, Explotab® CLV and Vivastar®), in particular, was 
demonstrated to be processable as a thermoplastic polymer and led to items with an intrinsic 
tendency towards disintegration that was rather unexpected in view of the low inherent 
porosity of extruded/molded products. Moreover, formulation strategies based on the use of 
soluble, disintegrant and effervescent adjuvants to promote tablet disintegration and drug 
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dissolution were successfully set up. Explotab® CLV-based units with different composition, 
prepared by both HME and IM, turned out to comply with the USP 37 dissolution 
requirements for furosemide thus pointing out an interesting application potential of these 
techniques for the production of IR tablets, which may ultimately be exploited for continuous 
manufacturing. 
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A PhD research project was undertaken aiming at investigating the possibility of 
transferring injection molding (IM)/micromolding (µIM) techniques to the pharmaceutical 
field for the manufacturing of drug products. With the main objective of identifying new 
potential areas of investigation, the overall information relevant to IM technology and its 
pharmaceutical applications already described in the scientific literature as well, were 
reviewed [Part I]. Hence, conventional dosage forms, i.e. immediate release tablets, and 
drug delivery systems (DDSs), i.e. gastroresistant capsular containers and hydrophilic 
swellable matrices, were successfully developed [Part II and III]. 
Since the ability of pharmaceutical polymers to undergo IM/µIM processes turned out 
poorly considered in the literature and, more generally, the identification of suitable 
materials was highlighted as a critical point in the development of molded drug products, a 
working procedure for a systematic evaluation of polymeric materials/composites was 
outlined within the research project. Pharmaceutical-grade polymers, either alone or in 
admixture, and polymeric composites with processing (e.g. plasticizers, reinforcements, 
lubricants) as well as functional (e.g. soluble and insoluble fillers, disintegrants, effervescent 
excipients) aids were evaluated leading to the construction of an extensive practical 
background. This work also helped to identify the need for developing a multidisciplinary 
approach to the problem based on thermal and rheological characterization of materials, 
engineering design of molds and set-up of processes as well as performance and stability 
evaluation of molded products. This knowledge has opened the way for scientific 
collaborations in the mechanical engineering and polymer science areas. Moreover, the 
experience gained from the research project, and in particular that derived from the 
evaluation of the feasibility of molded tablets with potential for immediate release, was 
profitably exploited during a nine-month internship at the Novartis-MIT Center for 
Continuous Manufacturing. The Center stems from a 10-year research collaboration 
between Novartis and the Massachusetts Institute of Technology (MIT), which is aimed at 
replacing the pharmaceutical industry conventional batch-based production mode with a 
continuous manufacturing one involving processing, without interruption, of materials 
generally maintained in motion and undergoing chemical reactions or mechanical/heating 
treatments. The research activity carried out at MIT is not included in my thesis because of 
confidentiality issues. 
As mentioned, IM/µIM are known to involve the use of molds specifically devised for one 
single item/material. Therefore, any change in the design and/or composition of dosage 
forms may require the development of new molds and manufacturing processes. In this 
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perspective, the real-time prototyping capabilities of three dimensional (3D) printing 
technology could turn out especially useful to speed up the screening of formulations and 
their transition to manufacturing as well as the identification of design characteristics of the 
device that could be critical for the performance. In fact, starting from a 3D model or 
other electronic data, such a technology allows solid objects of almost whatever shape to 
be manufactured. In particular, the fused deposition modeling (FDM) technique, which is 
based on the use of thermoplastic filaments, could prove suitable for achieving prototypes 
of IM/µIM products. Accordingly, some preliminary steps forward in coupling the design 
and the development of new devices by FDM 3D printing and in their scale up to 
industrial manufacturing by IM/µIM have been undertaken and are giving interesting 
insight.
  
 
